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ABSTRACT 
 
 
SHAUNTA S. PARKER 
 
A Geographic Information System (GIS) Analysis of Cancer Clinical Trial Locations in 
the State of Georgia by Major Cancer Type 
(Under the direction of Dr. Michael Eriksen, Faculty Member) 
 
Improving cancer care through clinical research is a major public health issue. However, 
in Georgia, the exact number of cancer clinical trials is unknown, indicating the need for 
baseline data regarding cancer clinical trial locations and cancer burden. This study 
provides the first statewide analysis of cancer clinical trial locations using Geographic 
Information Systems (GIS). This study examines cancer clinical trial locations by county, 
according to incidence rates, racial patterns and mortality rates of the four major cancer 
types: breast, colorectal, lung, and prostate. Findings from this study suggest that metro-
Atlanta counties have higher densities of cancer clinical trials. This study also found that 
there were little or no cancer clinical trials available in counties with the highest rates of 
overall incidence, African American incidence and overall mortality. This research 
demonstrates the need to increase availability of cancer clinical trials in counties with the 
highest cancer burden. 
 
 
INDEX WORDS: Cancer clinical trials, Geographic Information Systems (GIS), cancer 
burden, racial disparities, availability of cancer clinical trials 
 1
Chapter I – Introduction 
Cancer is the second leading cause of death in the state of Georgia.   
Approximately 13,500 Georgians die from cancer each year and an estimated 36,000 
Georgia residents are diagnosed annually. The most common forms of cancer in the state 
include breast, prostate, colorectal, lung cancer, accounting for 58 percent of all cancer 
diagnosed and 53 percent of all cancer deaths. Cancer is a serious public health issue that 
can be addressed in a variety of ways including prevention and treatment, particularly in 
cancer clinical trials (Singh et al. 2005). Cancer is commonly treated by surgery, 
radiation, chemotherapy, hormones, immunotherapy or a combination of two or more of 
these methods. Due to the severity of this disease, prevention and treatment of this 
disease have become increasingly important. Cancer treatment has improved over time 
due to advancements in clinical research (Ford et al. 2005). 
Clinical trials provide an important tool that assists in the advancement of 
research and cancer treatment, thereby reducing cancer mortality and in some cases 
morbidity (through prevention trials). Clinical trials are also vital in the determination of 
effective therapies for cancer treatment and prevention. For many patients, clinical trials 
provide an opportunity to receive cutting edge treatment (Comis et al. 2003).  
Yet, enrollment for cancer clinical trials across the state remains low (Murthy et 
al. 2004).  Researchers have conducted studies revealing reasons that cancer patients do 
not participate in clinical trials. Recent studies suggest that only 3 percent of cancer 
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patients participate in clinical trials (Sateren et al. 2002). This is scant compared to the 
fact that over 60 percent of children with cancer participate in cancer clinical trials. This 
issue has spurred numerous studies geared to identify barriers associated with cancer 
clinical trial enrollment. Numerous barriers to cancer clinical trial enrollment have been 
found, some of which include geography, racial obstacles and physician awareness (NCI 
2001). Racial obstacles regarding cancer clinical trial enrollment is a major public health 
issue due to the disproportionate burden of the disease. In Georgia, African American 
males are 20 percent more likely to be diagnosed with and 39 percent more likely to die 
from cancer than their white counterparts. In addition, breast cancer mortality rates for 
African American women in the state are 33 percent higher that Caucasian women. 
African American women in Georgia also experience colorectal cancer mortality rates 71 
percent higher than their white counterparts (Singh et al. 2005). Yet, African Americans 
have lower cancer clinical trial participation than whites (Corbie-Smith et al. 2004). It is 
important to ensure that clinical trial participants reflect the entire population and that 
cancer clinical trial results are generalizable (Etling et al. 2006).  
This issue gives rise to concerns of whether there is sufficient availability of 
cancer clinical trials for those most affected by the disease. Because there is no 
centralized cancer clinical trial database and the various cancer clinical trial registries are 
not linked, obtaining information regarding sufficient availability within the state can be 
daunting (McCray 2000). There is a national registry for clinical trials 
(www.clinicaltrials.gov), but it hosts trials for all diseases and may not always include 
local level details regarding specific locations for oncology practices. There is also a 
national database for cancer clinical trials, TrialCheck™ (www.trialcheck.org) which 
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supports the Georgia Cancer Trials database. This makes Georgia unique, as one of the 
few states in the U.S. with a state-specific cancer clinical trial database. Before the 
Georgia Cancer Trials database, monitoring and assessing the quantity and distribution of 
trials in the state was virtually nonexistent. This left Georgia grappling with many other 
states regarding the issue of whether there is sufficient availability of cancer trials for 
affected populations. 
 
Purpose of this study  
Utilizing data gathered from Georgia’s only statewide cancer clinical trial 
registry, Georgia Cancer Trials, this paper will reveal the geographic distribution of 
cancer clinical trials in the state and also expose racial disparity patterns in those areas. 
This thesis will use Geographic Information Systems (GIS) as an analysis tool to 
graphically display cancer clinical trial locations throughout the state. In an effort to 
address issues of information asymmetry, this thesis will provide baseline data regarding 
the geographic distribution of cancer clinical trials in the state, by cancer type, in a format 
that is consistent with the current cancer incidence reporting mechanism, GIS. This 
research will also show the racial patterns in those areas to provide information or details 
regarding the racial disparities in specific locations. The data will be presented at the 
county level.  
Viewing the geographic distribution of cancer clinical trials in Georgia through 
GIS mapping systems will create data that may assist with the state cancer plan and with 
potential strategic placement of needed cancer centers and cancer clinical trials across the 
state. It is hypothesized that many of the cancer clinical trials are located in the heavily 
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populated metro-Atlanta area, as opposed to rural areas where cancer clinical trial 
opportunities may be scant. Many times, rural areas of Georgia exhibit a higher cancer 
incidence rate than the metro-Atlanta areas. Obtaining data to confirm or refute this 
assumption is necessary in developing a strategic approach to advancing cancer clinical 
research in the state and determining if there are vast disparities in cancer clinical trial 
availability in specific areas.  
 
Study Objectives 
1) To identify the geographic distribution of cancer clinical trials in Georgia by 
cancer type. 
2) To examine the racial patterns of cancer incidence rates surrounding cancer 
clinical trial geographic locations. 
3) To establish baseline data for cancer clinical trial locations across the state. 
4) To make recommendations regarding strategic cancer clinical research 
improvement. 
 
Research Questions 
1) What is the geographic distribution of cancer clinical trials in Georgia? 
2) Are trials available in counties experiencing the highest burden of the disease? 
3) Is there a disparity in cancer clinical trial locations as it relates to racial pattern? 
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This paper will provide an analysis of cancer clinical trials in Georgia by major 
cancer type using GIS. The review literature will highlight issues related to cancer 
clinical trial participation and how GIS can be used in cancer clinical research. Chapter 
III will detail the methods and procedures used to analyze cancer clinical trials in the 
Georgia through the GIS ArcMap application based on the Georgia Cancer Trials 
database, cancer morbidity and mortality data. Chapter IV will reveal results found in this 
study, providing tables and maps to display where cancer burden is greatest versus where 
cancer clinical trials are located in the state. The final chapter will discuss details found in 
this study, answer the previously outlined research questions and make recommendations 
based on study results.  
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Chapter II- Review of Literature 
Cancer is a major cause of death in Georgia, accounting for 21 percent of all deaths in 
the state. In Georgia, prostate, breast, lung, and colorectal cancer are among the most 
common cancer types, accounting for 53 percent of all cancer deaths in the state (Singh et 
al. 2005), as seen in Figure 2.1. 
 
Figure 2.1 Leading Causes of Death, Georgia, 1998-2002 
 
 
 
 
 
 
 
 
 
 
 
 
*Source: Georgia Cancer Data Report, 2005 
 
There is great concern in the cancer research community regarding the low 
enrollment of cancer patients in cancer clinical trials. The need for more patients to enroll 
in trials has spurred the conduction of research to review why patients participate in 
cancer clinical trials. Many oncologists are concerned about whether there a sufficient 
 
 7
trials available. According to the Georgia Department of Human Resources, Division of 
Public Health, an estimated 39,520 Georgians were diagnosed with invasive cancer in 
2006. Recent studies suggest that burden of disease is higher in rural areas of Georgia, 
compared to metro areas. According U.S. statistics, males have a 1 in 2 lifetime risk of 
developing cancer while women have a 1 in 3 lifetime risk. The severity of this disease 
gives implications for the importance of cancer clinical trials and developing a cure for 
the disease (Singh et al. 2005).  
This review of literature will discuss cancer clinical trial basics and registry issues. In 
addition, the following topics related to cancer clinical trial participation will also be 
reviewed: racial/ethnic issues, socioeconomic status and cancer trials, effects of distance 
and cancer trial locations. It is important to review these topics not only because they are 
directly related to the research conducted in this paper, but also because they encompass 
the various reasons why patients enroll in cancer clinical trials.  
 
Cancer Clinical Trials Background  
Clinical trials represent how advancements in research are made and answer 
important questions regarding whether a cancer drug is safe and effective. This section 
will describe the various phases of cancer trials, types of cancer trials, and levels of 
prevention in cancer trials.  
There are 4 phases to cancer clinical trials. Phase I cancer trials evaluate how new 
drugs should be given, how often they are given, and what dose is safe in humans. Phase 
II cancer trials test the safety of the new drug, and begin to evaluate how well the new 
drug works on a particular cancer type. Phase III cancer trials test a new drug, a 
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combination of drugs, or a new surgical procedure in comparison with the current 
standard of treatment. Phase IV cancer trials review the long term safety and benefits of a 
treatment. This phase continues after the study treatment has been approved for use and 
doctors are able to give it to patients routinely. These trials can be used to gather 
information on any side effects that may have been missed in the earlier trials (NCI 
2001). Figure 2.2 below exhibits how cancer clinical research translates into patient care. 
 
Figure 2.2 How Cancer Research Moves into Patient Care 
 
* Source: Coalition of Cancer Cooperative Groups, 2006 
In addition, cancer clinical trials can also be categorized by type of trial, including 
prevention, treatment, supportive care and other. Prevention studies reveal ways of 
reducing the risk of getting cancer in one of two ways: by doing something, such as 
exercise or quitting smoking (Action studies), or by taking something, such as certain 
medicines, vitamins or minerals (Agent studies). Treatment studies test new treatments 
such as the following: new cancer drug, new approaches to surgery or radiation therapy, 
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new combinations of treatments, or new methods such as gene therapy. Supportive care 
studies work to find better methods for caring for the side effects caused by cancer 
treatment and the side effects of the cancer itself. Many supportive care studies use drugs 
to treat the side effects. Supportive care is given to improve the quality of life for patients 
with serious diseases (NCI 2001).  
There are three levels of prevention in cancer clinical trials: primary, secondary, and 
tertiary prevention. Primary prevention trials are designed to intervene among people 
with cancer risk profiles; the objective is to eliminate exposure that could trigger 
mutagenesis or carcinogenesis (i.e., in occupational settings). Secondary prevention trials 
identify genetic markers, biomarkers, or early diagnosis and clinical manifestation (i.e., 
breast lump, skin lesion, or persistent cough) to stop the process through drugs prior to 
serious disease manifestations. Tertiary prevention involves surgical ad adjuvant 
chemotherapies or natural remedies to rehabilitation to ensure maximal quality of both 
function and life (NCI 2001). 
 
Cancer Clinical Trial Registries  
Because the Georgia Cancer Trials registry is a major data source for this paper, it 
is important to discuss mandates for cancer clinical trial registries, issues associated with 
maintenance of cancer clinical trial registries, and patient utilization of cancer clinical 
trial registries.  
There are federal mandates requiring the listing of cancer clinical trials in a 
database (Hillner 2004). In 1997, a section of the FDA Modernization Act required 
creation of a clinical trials database: 
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A registry of clinical trials (whether federally or privately funded) of experimental 
treatments for serious or life-threatening diseases and conditions….which provides a 
description of the purpose of each experimental drug, either with the consent of the 
protocol sponsor, or when a trial to test effectiveness begins. Information provided shall 
consist of eligibility criteria of participation in the clinical trials, a description of the 
location of trial sites, and a point of contact for those wanting to enroll in the trial, and 
shall be in a form that can be readily understood by members of the public (McCray 
2000). 
Cancer clinical trials databases in the US include (but are not limited to) the 
following: NCI, NIH registry, National Coalition for Cancer Cooperative Groups, 
Oncolink, TrialCheck and Centerwatch (NCI 2001). Though there are federal mandates 
for clinical trials registration, trials are registered through various databases and 
oftentimes patients are unaware of cancer clinical trial options (McCray 2000). The 
Georgia Cancer Trials database is powered by TrialCheck which means that the 
nationally registered data is filtered into the state-specific database with more details 
regarding actual locations of oncology practices and contact information. Georgia CORE 
also adds cancer clinical trials conducted at community practices to the database that may 
not be captured at the national level. In addition, the information regarding trials in the 
database is sent to the oncology practices for frequent updates, which ensures that the 
database is a true representation of oncology clinical research in Georgia. Therefore, the 
Georgia Cancer Trials database is a more accurate picture of where cancer clinical trials 
are located in the state.  
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Dickersin and Rennie (2003) reviewed the importance of clinical trial registration. 
They highlighted the need to develop a comprehensive cancer clinical trial registry, 
particularly since it is not currently possible to find information regarding all initiated 
cancer clinical trials in a central location. This is important because clinical trial registries 
are used by physicians and patients to identify which studies are open for enrollment 
(Dickersin and Rennie 2003). 
Alexa McCrary (2000) conducted a study to investigate associated with cancer 
clinical trial registries. McCrary’s study found numerous issues with maintaining clinical 
trial registries, some of which included that they required extensive resources to create 
and maintain the database; required agreement on standard data elements; required 
managing data from multiple sources; required regular updates to ensure accuracy; raised 
proprietary concern; and involved technical challenges. He also found that there were 
numerous benefits associated with clinical trial registries. For example, they served as 
resources for patients, physicians and researchers; helped patients find trials for which 
they might be eligible; assisted in accrual of patients; helped physicians identify 
treatments under study; and helped in the initiation and design of new trials (McCray 
2000).  
Wei and colleagues (2004) discussed utilization of an internet-based database to 
enroll patients in cancer clinical trials. This study highlighted the increasing use of 
internet for patient resources and information regarding cancer clinical trial availability. 
Wei and others (2004) reviewed how cancer patients access information regarding 
clinical trials by surveying patients who enrolled through internet-based database vs. 
telephone call center enrollment. They found that most registrants (88 percent) accessed 
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information through the internet. They also found that participants who registered 
through the internet were significantly younger than those who registered through the call 
center (Wei et al. 2004). 
 There are many determining factors of cancer clinical trial participation. The 
following content will discuss issues associated with patients’ decision to participate in 
cancer clinical trials: cancer clinical trial availability, racial/ethnic issues, socioeconomic 
status, and effects of proximity to trial locations. 
 
Cancer Clinical Trial Availability 
Registries are important in assisting patients with locating cancer clinical trials; 
however, an adequate number of trials must be available. Meyer et al. (2006) conducted a 
study at the Gundersen Lutheran Cancer Center in Wisconsin to evaluate clinical trial 
accrual among patients, as well as the availability of trials for adult cancer patients with 
recurrent or progressive cancer treated in the community. They conducted a retrospective 
analysis of a specific group of patients who received chemotherapy at the Gundersen 
Lutheran Cancer Center from November 2004 to October 2005. They also collected data 
regarding the number, sources, and types of cancer clinical trials that were available. 
They found that 50 trials were offered, with approximately half of the trials being for the 
following cancer types: lung (14 percent), pancreatic (12 percent), renal (10 percent), 
head and neck (8 percent), prostate (6 percent), and breast (6 percent). There were no 
trials offered in the areas of bladder, colorectal, and gastrointestinal cancers. Of all 
participants, only 69 patients (49.3 percent) had trials appropriate for their cancer type 
and stage of cancer. Among the patients with available trials, 24 (34.8 percent) were 
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eligible to participate. Six of the eligible patients were enrolled in trials, bringing the 
overall accrual rate to 4.3 percent (Meyer et al. 2006). 
 Meyer et al. (2006) identified 140 patients, with an equal number of males and 
females and a median age of 66 years at the time of treatment. They concluded that 
enrollment was low for cancer patients with recurrent or progressive cancer. More than 
80 percent of their cancer patients were denied access to a cancer trial due to protocol 
unavailability and ineligibility. As a result, researchers found that cancer cooperative 
groups did not provide an adequate number of cancer clinical trials for patients in the 
community (Meyer et al. 2006). 
  Lara and colleagues (2001) conducted a study to evaluate accrual patterns of 
cancer clinical trials and to determine potential barriers associated with trial enrollment. 
These factors were reviewed because low cancer clinical trial accrual rates may lead to 
negative impacts that prolong cancer trial duration, force early closure of key studies and 
delay the analysis of essential results. Based on their survey of physicians, they found 
that protocol availability was a major factor affecting cancer trial accrual. They also 
found that of the 62 percent of patients that physicians considered for clinical trials, 47 
percent of them had no available protocols at the time of the survey. Lara and colleagues 
(2001) also found that physicians who refrained from informing patients about cancer 
clinical trials cited that the perception that there were no available protocols appropriate 
for the patient’s specific tumor site and stage was the most common reason for doing so. 
This is an important concept that leads back the unequal gradient of information or 
information asymmetry. Because physicians perceived that there were no trials available, 
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based on their lack of information, many patients were not offered cancer clinical trials as 
treatment option (Lara et al. 2001).  
A study on barriers to cancer trial accrual was conducted by Baggestrom and 
colleagues (2006) and presented at the 2006 American Society of Clinical Oncology 
(ASCO) meeting. In this study, Baggestrom et al. (2006) reviewed outpatient charts for 
all patients with thoracic malignancies that were referred by the thoracic medical 
oncology group from their institution, including non-small cell lung cancer (NSCLC), 
esophageal cancer, and small cell lung cancer. They found that the most common reasons 
for nonparticipation included protocol ineligibility and geographic issues. Baggestrom 
and colleagues (2006) also found that 35 percent of patients were not enrolled in cancer 
clinical trials because there was a lack of available appropriate trials during the initial 
consultation period. (Baggstrom et al. 2006).  It is important to address issues associated 
with availability of cancer clinical trials, particularly since a survey conducted by Comis 
and colleagues (2003) found that 92 percent of respondents felt that cancer clinical trials 
would benefit themselves and others (Comis et al. 2003). It is imperative that appropriate 
trials be available to those who desire to participate in research studies.   
The number of available cancer clinical trials depends heavily on physician 
participation. Somkin and colleagues (2005) identified barriers to physician participation 
in cancer clinical trials. Their study found that 63 percent of oncologists agreed that 
cancer clinical trials were their treatment choice if available. In addition, nearly 90 
percent of the oncologists established that clinical trials provide high quality care. 
Somkin et al. (2005) also noted the following barriers to physician involvement in cancer 
clinical trials: lack of support staff, lack of information about trials, effort and time for 
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informed consent, inadequate money from sponsors, and reduced time for other patients 
(Somkin et al. 2005). 
It is important to note that at large medical centers like NCI designated cancer 
centers, physicians are expected to participate in cancer clinical research in the quest for a 
cancer cure and better cancer treatments. Conduction of clinical research by physicians in 
community practices is vital in order to increase the availability of cancer clinical trials 
(Albrecht et al. 1999). This need was identified by NCI and they developed the 
Community Clinical Oncology Program (CCOP) in 1983, in an effort to increase clinical 
trial accrual and clinical research involvement. This NCI program allows community 
oncologists the opportunity to compete for funding to support their cancer clinical trials 
program through a recognized research base, such as the Eastern Cooperative Oncology 
Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Leukemia Group B 
(CALGB), etc. This program is limited to physicians who are associated with hospitals 
that have the capacity to maneuver through the grant process (Cohen 2003).   
 
Racial/Ethnic Issues Associated with Cancer Clinical Trial Participation 
Cancer clinical trial participation is low among minority populations. In fact, the 
proportion of African American participation has declined over the years (Murthy et al. 
2004). Advani and colleagues (2003) conducted a study to understand barriers associated 
with cancer trial enrollment in the African American community. This study surveyed 
218 cancer patients (72 African American and 146 white patients) from the Duke Cancer 
Center and the Duke Oncology Outreach Clinics. They found that more African 
American patients than white reported that transportation and cost posed problems with 
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access to the clinic. They also noted that the under representation of African Americans 
in cancer trials has three major impacts: 1) research findings cannot be generalized to the 
entire population when there is questionable applicability to groups of ethnic decent; 2) 
certain types of malignancies occur more frequently in various racial/ethnic groups; and 
3) many reports have called attention to the power of survival among African American 
and Hispanic patients, compared with white patients (Advani et al. 2003).  
Baquet and colleagues (2006) investigated predictors of cancer clinical trial 
participation in Maryland residents in underserved geographic areas. They found that 
among patients recruited to cancer trials, African Americans were significantly less likely 
to participate. They also found that childcare and transportation were determining factors 
in cancer clinical trial participation, specifically in African American women (Baquet et 
al. 2006).  
Baquet et al. (2006) also noted several reasons for disparities in clinical trial 
participation including the following: availability of trials primarily in academic and non-
community settings, patient, community, and health professional barrier; historical 
factors such as the Tuskegee Syphilis Study and other examples of unethical and 
exploitative research; reimbursement issues and concerns and study design issues such as 
use of randomization for group assignment, blinding and placebos (Baquet et al. 2006). 
These findings were particularly important because in many states, minority and rural 
communities suffer distinct disadvantages in accessing quality health care services and 
health professionals for cancer prevention, screening, early detection, treatment, 
palliative care, and pain management. Generally, African Americans, other minority 
populations, rural communities, and uninsured populations have participated in cancer 
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clinical trials less than other groups. Due to these disparities in research participation, the 
benefits of standardized quality care in clinical trials and advances in the research are not 
equally distributed to all communities (Petereit et al. 2005).  
Adams-Campbell and colleagues (2004) studied factors associated with enrollment of 
African Americans onto cancer clinical trials at Howard University over a two year 
period. They found that thirteen cancer treatment trials were approved and opened during 
the course of the study. They also found that there was an eligibility rate of 8.5 percent, 
with a conditional enrollment rate of 60 percent. Adams-Campbell et al. (2004) also 
found that there were no appropriate trials available for 24.2 percent of the patient 
population. Co-morbidity of disease caused 17.1 percent of the patients ineligibility for 
the studies (Adams-Campbell et al. 2004). This is important because many African 
American patients suffer from co-morbidity of diseases that may exclude them from 
enrolling in cancer clinical trials.   
Brown and colleagues (2000) conducted a study to investigate issues associated with 
enrollment of cancer clinical trials among minority women. In this study, they 
interviewed newly diagnosed breast cancer patients of the Harper Hospital in Detroit, 
Michigan to identify barriers to participation in cancer clinical trials. They also assessed 
eligibility of trials and documentation of cancer clinical trial participation. Barriers 
identified by African American women included lack of information, fear and perceived 
interference with personal responsibilities (Brown et al. 2000).  
Fouad and colleagues (2000) held a conference in Tuskegee, Alabama to understand 
factors involved in minority recruitment in cancer clinical trials. This meeting engaged a 
workgroup of healthcare professional to identify barriers to minority recruitment to 
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cancer clinical trials. In this study, physicians in the workgroup noted the following 
barriers to minority enrollment in cancer trials:  lack of knowledge of available resources, 
poor communication between patients and physicians, and lack of appreciation of the 
need for clinical trial. Fouad et al. (2000) also found that awareness of the Tuskegee 
Syphilis Experiment did not affect cancer clinical trial participation. However, this 
finding is not consistent with previous studies that have cited minorities’ distrust of 
scientific investigators, government and academic institutions based on the inappropriate 
conduct regarding the Tuskegee Syphilis Experiment (Fouad et al. 2000).  
There is a substantial need to address issues related to minority participation in cancer 
clinical trials. Because decreasing minority cancer clinical trial participation is a major 
issue, barriers such as: fear, mistrust, inadequate access to trials, protocol ineligibility, 
cultural myths, and transportation costs must be addressed in a calculated manner 
(Newman et al. 2006).  This is particularly important because more minorities are needed 
to participate in cancer clinical trials. This not only helps to increase the generalizability 
of cancer clinical trial results (Moinpour et al. 2000), but it also helps determine if there 
are genetic or cultural differences which impact cancer outcomes (VanEenwyk et al. 
2002).  
Low-income populations deal with socioeconomic issues that may prevent them from 
participating in cancer clinical trials (Abou-Jawde et al. 2006). The next section will 
discuss socioeconomic issues associated with cancer clinical trial participation. 
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Socioeconomic Status and Cancer Clinical Trial Participation 
 Socioeconomic status (SES) also plays a role in cancer clinical trial participation. 
Sateren and colleagues (2002) conducted a study to examine the influence of SES on 
accrual of patients to NCI-sponsored cancer treatment clinical trials. They assessed how 
cancer patients accrued to these trials using a range of socioeconomic, geographic, and 
demographic variables as indicators. They also estimated the geographic and 
demographic US cancer burden using Census data and NCI Surveillance, Epidemiology, 
and End Results (SEER) incidence data, since there is no national cancer reporting 
mechanism. By combining census and cancer incidence data, researchers developed a 
sketch of the demographic and geographic patterns of cancer in the U.S. Sateren and 
colleagues (2002) then calculated the expected number of cancer patients accrued to 
trials, by geographic level. They studied the number accrued by age, sex, health insurance 
status, geographic location, SES, average income on county level, and county education 
level (Sateren et al. 2002).  
Sateren et al. (2002) found that the highest percent of adult patients accrued to 
trials was between 40 and 55 years of age. The majority of patients enrolled were female 
(56 percent). They compared this with SEER data, which indicated that 47 percent of 
newly diagnosed patients were female and 53 percent were male. They also found that 
there were 119 trials open with women sex-specific cancers and 27 trials open with men 
sex-specific cancers. Additionally, the percentage of white patients enrolled in cancer 
clinical trials was parallel to the overall population statistics. The percentage of African 
American men with cancer and were between 30 and 59 years of age and accrued to a 
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clinical trial was lower than the percentage of white men with cancer in the same age 
group (Sateren et al. 2002). 
 Sateren and colleagues (2002) used several measures to determine SES, including 
mean county education level, mean county income level, mean county poverty level and 
mean state employment rate. Including all measures, areas with higher socioeconomic 
levels had significantly higher levels of clinical trial accrual. Also, urban areas with the 
largest county incomes had the highest rates of observed clinical trial accrual rates. They 
also found that each percentage increase in unemployment was associated with a drop in 
observed accrual of almost 37 patients per state, whereas each additional approved cancer 
program increased accrual by more than nine patients per state. Also, there were 36.5 
fewer patients per 1 percent increase in state unemployment. This study was limited to 
enrollees over a 12-month period and data for approximately 24,000 patients. Also, 
researchers were limited to data regarding NCI-sponsored cancer clinical trials. In 
addition, the study did not include patients accrued from pharmaceutical trials (Sateren et 
al. 2002). 
SES is an essential predictor of access to cancer care. It is important to understand 
how this factor relates to age and race disparities in cancer clinical research. Gross and 
colleaugues (2004) conducted a cross-sectional analysis of patients enrolled in NCI 
sponsored lung, colorectal, prostate, and breast cancer clinical trials. For each of the four 
cancer types, researchers selected 10 cooperative group trials that enrolled the most 
patients during the study period. They focused primarily on older women; therefore, trials 
with fewer than 5 percent of elderly patients (aged 65 or less) were not included. As a 
proxy for SES, researchers used each patient’s zip code to link to the 2000 US Census 
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data and derived the proportion of participants living in areas below poverty level. Gross 
and colleagues (2004) utilized a stepwise approach to identify discrete recruitment 
centers in the Clinical Trial Evaluation Program database. To ensure accuracy, research 
assistants used several data sources, including the internet and direct telephone contact 
(Gross et al. 2004).  
 Gross and colleagues (2004) found that low SES was significantly associated with 
clinical trial enrollment, even after adjusting for variables such as age, race, and 
proximity to the nearby cancer research center. Results from this study also suggest that 
African Americans with Medicaid were generally less likely to participate in cancer 
research trials than whites. They also found that that white patients were significantly less 
likely to reside in areas of high poverty (Gross et al. 2004).  
 According to Giuliano and colleagues (2000), there are three major reasons why 
individuals with lower SES do not participate in cancer clinical trials. First, having lower 
SES may result in lower rates of screening and prevention and a higher dependence on 
public hospitals where physicians are less likely to be involved in cancer clinical 
research. Second, patients with lower SES may have insurance issues, mainly because 
they may be more reliant on Medicaid and Medicare insurance. This is unfortunate 
because reimbursement with participation in a clinical trial is inconsistent and often 
denied by Medicaid and Medicare. Third, concerns with financial survival may take 
precedence over health and well-being. Oftentimes, patients with low SES are 
discouraged from engaging in cancer prevention and screening activities (Giuliano et al. 
2000).  
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Presence or absence of managed care is also an important factor in cancer clinical 
trial participation, particularly regarding a physician’s decision to inform patients about 
cancer clinical trials (Grunfeld et al. 2002). As indicated by Gross and Krumholz (2005), 
managed care plays a substantial role in physicians’ behavior regarding cancer clinical 
trial enrollment. Enrolling patients to cancer clinical trials requires a significant 
investment of time and money. Clinician-investigators and their staff expend an estimated 
150-450 hours enrolling patients to cancer clinical trials, with costs ranging from $1300 
to $3900. While resources are scarce and reimbursement structures are static, increasing 
demands of clinical trial enrollment are an additional strain. Decreases in clinical 
revenues associated with managed care organizations have made many physicians less 
reluctant to devote additional resources for cancer clinical trial enrollment (Gross and 
Krumholz 2005).  
SES is also related to a patient’s ability to travel to oncology practices. Because 
travel distance may provide another barrier, it is important to discuss how proximity to 
the research facility effects the patient’s decision to enroll in a clinical trial. The next 
section will provide a review of this issue.    
 
Effects of Proximity to Trial Locations 
It is important to understand how travel distance to cancer facilities effect cancer 
clinical trial participation (Athas et al. 2000). Gross and colleagues (2004) analyzed the 
effect of travel distance on enrollment of elderly patients to cancer trials. They found that 
the geographic location of trial participants was important in 2 ways. Both travel distance 
from the trial recruitment center and underlying age distribution of the population were 
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related to recruitment of older persons. They also found that participants who lived within 
7 miles of a recruitment centers were significantly more likely to be elderly. This is 
consistent with other research suggesting that travel time is a frequent reason for 
declining to enroll in a clinical trial (Gross et al. 2004).  
This is important because enrolling onto a study may often entail undergoing treatment 
and clinical assessments in facilities that are further away from the patients’ home than 
they would otherwise use (Nattinger et al. 2000). Elderly persons may have more barriers 
to travel due to impairments in mobility or cognition (Gross et al. 2004).  
A study conducted by Lamont and colleagues (2003) suggests that patients who 
travel farther to enroll in a study have better survival (Lamont et al. 2003). Considered 
with findings from the Gross et al. study, it is likely that not only are older persons less 
likely to travel longer distances to enroll in cancer clinical trials, but those who do may 
be a healthier subset of the elderly. Therefore, facilitating travel by addressing logistic 
barriers for older persons may improve not only the number of older persons enrolled in 
clinical trials but also the generalizability of the results by enabling patients with a broad 
spectrum of health status to enroll (Gross et al. 2004).  
It is important to have a general understanding of how far patients travel to 
participate in cancer clinical trials. Wright and colleagues (2004) conducted a study to 
identify the independent predictors of patients’ decisions to enter phase III clinical trials. 
A single institution observational cohort study design was employed, using a series of 
questionnaires developed to capture trials-related opinions of patients, their physicians, 
and clinical research associates. They found that mean reported travel distance to the 
cancer center was 38km, ranging from 1- 166km (Wright et al. 2004).  
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Gross and Krumholz (2005) conducted an investigation to determine the 
relationship between managed care patients and cancer clinical trial enrollment. They 
collected data from NCI Cancer Trials Evaluation Program for participation in NCI-
sponsored cooperative group breast, lung, prostate, and colon cancer trials. Trial 
participants were assigned to counties according to zip code of their residence. 
Geographic Information System (GIS) data were used to estimate distance, in linear 
miles, between the center of each county and the nearest county that had an NCI research 
center. County SES was related to trial enrollment. Counties with higher proportions of 
their population living below poverty level had substantially lower median enrollment 
rates, decreasing from 19.1 in counties with less than 9.1% below poverty to 14.0 in 
counties with the highest poverty level. Counties with NCI research centers had a median 
rate of 21.7, while counties more than 36.5 miles from the nearest center had a median 
rate of 15.5 (Gross and Krumholz 2005).  
In Gross and Krumholz’s study, counties with the highest enrollment fraction 
were less likely to have 2 or more hospitals with oncology services and tended to be non-
urban. In this study, the presence of teaching programs and hospitals was unrelated to 
trial enrollment. Urban counties at increasing distance from a research center and with a 
higher proportion of the population uninsured or below poverty also tended to have lower 
enrollment rates in the multivariate analysis (Gross and Krumholz 2005). 
Celaya and colleagues (2006) studied whether proximity to a radiation treatment 
facility (RTF) played a role in the treatment choice of women with early-stage breast 
cancer. They hypothesized that proximity of the treatment facility to patients’ residence 
may play a role in cancer treatment, particularly in rural populations.  Their study 
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identified all radiation treatment facilities in the New Hampshire, Maine, Massachusetts, 
and Vermont over 4 years. Celaya et al. (2006) geocoded the addresses of each facility 
and each patient’s address using Geographic Data Technology (GDT) to an exact street 
address or zip code. They also estimated the shortest straight-line distance to a facility 
(Celaya et al. 2006).  
Celaya and colleagues (2006) found that the average distance between patients’ 
residence and the nearest RTF was 15.1 miles (ranging from 0.1-89.9 miles; median 
13.9). Nearly 25 percent of patients lived greater than 20 miles way from the nearest 
RTF. In a multivariate analysis, they also found that women were less likely to have 
treatment (breast conserving surgery) with increasing distance from the their residence to 
the RTF (Celaya et al. 2006).  Issues associated with travel distance are extremely 
important in rural areas in which patients may be required to drive farther distances for a 
cancer clinical trial.  
Paskett and colleagues (2002) conducted a study to investigate cancer clinical trial 
enrollment factors in rural patients living in North and South Carolina. In this study, 
access to the clinical trial center and transportation as barriers as factors for participation 
in cancer clinical trials (Paskett et al. 2002). This study also found that cost and 
unfamiliarity of physician were also factors that affected clinical trial participation rates 
in rural cancer patients. There are also geographic differences in cancer clinical trial 
accrual.  
In a study conducted by Sateren and colleagues (2002), geographic differences in 
clinical trial accrual were found. Specific states and regions of the US had significantly 
lower or higher accrual to clinical trials than the national accrual figures. Northern states 
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such as Delaware, Iowa, Minnesota, New Hampshire, and North Dakota had the highest 
clinical trial accrual rates per number of cancer incidence cases, whereas southern states 
such as Alabama, Arkansas, Florida, West Virginia, Kentucky and Georgia had the 
lowest accrual rates per number of cancer incidence. Generally, researchers observed 
higher clinical trial accrual rates in suburban areas (Sateren et al. 2002). 
 
 
Geographic Information Systems (GIS) 
GIS combines computer hardware, software, databases, and personnel to manage, 
display, map, and analyze information related to spatial phenomena. The term 
“geographic information systems” was first used in the 1960s to refer to a computer 
system for asking questions of maps showing current and potential land use in Canada 
(Richards et al. 1999). GIS technology provides public health researchers and officials 
with numerous new types of data. GIS can be used to analyze geographic patterns of 
disease. The software displays spatial and temporal patterns of health outcomes (Cromley 
2003). GIS information must be compatible with the other software used for analysis; 
therefore, geocoding is performed to create geographic points from data that may not 
have otherwise been analyzed by this software (Rushton 2003).  
Geocoding is a calculation of spatial locations from street addresses. Geocoding 
in ArcView GIS is a process that creates a layer of visual information based on locational 
data in tabular form and a reference feature theme. Compared with tools and charts, maps 
developed using GIS technology can be an extremely effective tool to assist stakeholders 
and decision makers in visualizing and comprehending public health problems. However, 
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the use of GIS for community health planning and various public health applications 
remain a relatively underdeveloped marketplace niche (Rushton et al. 2006).  
Basic uses for GIS mapping when visualizing cancer data have been studied by 
C.A. Brewer (2006). This study identified various mapping methods and discussed how 
each method helps researchers visualize cancer data. Mapping methods included: 
chloropleth mapping, color symbols, classing, and proportional symbols (Brewer 2006). 
GIS can be used to examine inference. According to Geoffrey Jacquez (2004), strong 
inference begins with a set of hypothesis regarding observed phenomena. Researchers 
then design a series of critical experiments to systematically test each hypothesis. Spatial 
systems typically are large and the spatial phenomena of interest in public health (i.e., 
cancer mortality rates, risky behaviors, demographic changes, and experimental 
exposures) are difficult to observe directly and/or change slowly through time. This 
makes it difficult, if not impossible, to conduct designed experiments and in any event 
there are substantial ethical consideration with experimentation on human population 
(Jacquez 2004).  
 Spatial health researchers must often work with encountered data that have been 
collected for some purposes other that her specific study. In many instances, the data are 
sampled in a systematic way from a spatially distributed population. However in some 
instances spatial analysis plays a critical role in identifying spatial and temporal 
relationship in population level data, giving rise to hypothesis that can be evaluated on 
additional data to be collected from the same system or on data from analogous spatial 
systems (Jacquez 2004).  
 
 28
 The spatial analyst toolbox includes techniques for quantifying spatial patterns, 
modeling risk surfaces, and assessing relationships between cancer outcomes and 
potential exposures. These techniques allows researchers to determine whether observed 
spatial patterns are statistically significant, to identify the locations of clusters, hot spots 
and cool spots, to construct maps, showing excess and deficits relative to a risk model, 
and to quantify association between 2 spatial variables (Jacquez 2004).  
 Recently, GIS has been used to show spatial patterns of cancer morbidity and 
mortality trends (Boscoe et al. 2004). This is important for this paper because this GIS 
analysis of cancer clinical trials in Georgia joins various data sets to determine if cancer 
clinical trials are offered in areas with the highest rates of cancer incidence and mortality. 
Spatial patterns will display the relationship between where clinical trials are located and 
where disease burden is greatest.   
 
Theoretical Approach in this Study 
Disparities in cancer treatment are apparent and researchers agree that it should be 
addressed in a strategic manner. However, there is uncertainty regarding the state of 
cancer clinical trials and whether there is sufficient availability of cancer clinical trials in 
needed areas. This has led many to question whether clinical trials are available for 
vulnerable populations. The literature suggests that this type of analysis has not been 
graphed on a statewide basis; however, there are few studies conducted at research 
centers that address the problem for their particular cancer center. This may lead to 
information asymmetry.  
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Information asymmetry is a theory that is commonly used in economics to explain 
market failure (Smith 2005). For the purposes of this paper, information asymmetry is 
defined as the disproportionate gradient between those with knowledge regarding cancer 
clinical trials in the state and those who lack the information. In this case, Georgia CORE 
would be the information holders and physicians, public health officials, patients, and 
advocates that aren’t equipped with the data are at the opposing end of the gradient. 
Generally, GIS has been particularly useful in examining cancer incidence and 
mortality rates in the U.S. Furthermore, these methods can be used to investigate a 
number of geospatially-related questions. While there is no survey associated with this 
thesis study, research results from this study will provide baseline details that address 
barriers found through previous studies: geographic locations and racial patterns.  
 
What is unknown 
There is currently no statewide analysis of cancer clinical trials for Georgia. In 
addition, there is no report with baseline data regarding the number of cancer clinical 
trials offered in the state by cancer type and cancer clinical trial location. Consequently, 
there is no consensus on whether an adequate number of clinical trials are being offered 
throughout the state, particularly for underserved populations. Therefore, this thesis will 
identify baseline data regarding cancer clinical trial locations across the state by major 
cancer type (i.e., breast, colorectal, prostate, and lung). This paper will also explore racial 
patterns surrounding areas with cancer clinical trials as an indicator for appropriate access 
to trials in the state. GIS will be utilize to address this information asymmetry and 
provide a more precise measure for assessing this problem in a manner that is consistent 
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with current cancer morbidity reporting mechanisms. The next section will describe the 
methods and procedures used to identify, collect, and analyze data in this study. 
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Chapter III- Methods and Procedures 
Availability and access to cancer clinical trials are important in securing the 
quality of cancer care, access to promising therapies and enrollment of cancer patients to 
trials. Because cancer clinical trials rely heavily on volunteer participation, it is crucial 
that there are appropriate numbers of trials available to needed populations. An adequate 
number of trials must be present in order for patients who qualify for the study to enroll. 
The exact number of cancer clinical trials is currently unknown across the state. Many 
oncologists and health officials are left to guess regarding the number of cancer clinical 
trials are in Georgia and their locations. The state-specific, Georgia Cancer Trials 
database provides a link to the information asymmetry occurring regarding the clinical 
trial availability. The database is provided through the Georgia Center for Oncology 
Research and Education, Inc. (Georgia CORE). It is made available through a partnership 
between Georgia CORE and the Coalition of Cancer Cooperative Groups. 
This study was granted exempt-review from the Georgia State University 
Institutional Review Board, protocol number H07279: approval letter number 17718. Dr. 
Michael Eriksen was listed as the Principal Investigator and Shaunta Parker as the 
Student Principal Investigator.  
This study was conducted to understand where cancer clinical trials are located by 
major cancer type and determine if cancer clinical trials in Georgia were offered in 
counties with highest disease burden, using GIS. Also, geographic racial patterns 
regarding cancer incidence rates were taken into account in order to determine if 
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adequate trials were offered in disparate populations where the disease burden may be 
greater. Generally, GIS analysis takes a stepwise approach, from defining the problem to 
examining and displaying the results, as seen in Figure 3.1. 
 
Figure 3.1 GIS Analysis Process Map 
   
*Source: ESRI, 2007 
The process map displayed in figure 3.1 outlines the method of analysis used in 
this study.  In this study, the problem is defined as the lack of information regarding 
where cancer clinical trials are located in Georgia and whether trials are offered in 
counties most affected by the disease.  
The next step, using the GIS process map as a guide, defined the criteria for this 
study. The following factors were included in this study: open active adult cancer clinical 
trials and their corresponding oncology practices in Georgia. The study did not include 
childhood cancer clinical trials. The dependent variable of this study includes the quantity 
of cancer clinical trials. Factors evaluated in this study include counties with trials, cancer 
incidence and mortality rates by major cancer type and African American cancer 
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incidence rates. The design of this study called for the listing of all cancer clinical trials 
along with their corresponding addresses for mapping purposes. In order to view trial 
locations in the ArcView GIS application, each cancer clinical trial listing required 
geocoding.  
The next step, based on the process map in figure 3.1, identified the data required 
for this study. Cancer clinical trial location information was collected from the Georgia 
Cancer Trials database; GIS county shapefile data was collected from the Office of 
Health Information and Policy’s website; and cancer morbidity and mortality data was 
collected from the Georgia Comprehensive Cancer Registry. Initial data collected from 
the Georgia Cancer Trials database included the total number of cancer clinical protocols 
and the total number of trial listings offered to adult cancer patients in the state. Data was 
collected on all adult cancer trials to obtain a total number of cancer clinical trials in 
Georgia. The first set of data regarding cancer trial information was collected in October 
2006. A report was requested from the national TrialCheck database for all of adult 
cancer clinical trials listed in the Georgia Cancer Trials database. Upon receipt of the 
report, the information was entered into a Microsoft excel spreadsheet. Clinical trials 
were characterized by the following: protocol identification number, Cancer Therapy 
Evaluation Program identification number (CTEP ID), oncology practice name, cancer 
type, trial type (i.e., treatment, prevention, supportive care, or other), and address. 
Official protocol identification numbers were used to verify each protocol to ensure that 
there were no duplicates. It is important to note the difference between what is described 
as a protocol versus a cancer clinical trial listing in this study. Protocols refer to the 
description of rules of how the study is to be carried out and the study purpose. Each 
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study has a definitive protocol number that is unique to that specific trial. The number of 
protocols is different from the number of cancer clinical trial listings because the listings 
include the various locations in which protocols are offered. For example, if protocol A is 
offered at 12 sites across the state then the protocol has 12 listings that should be included 
when reviewing the number of trials.   
Some oncology practices had numerous CTEP IDs, depending on how the trials 
were initially entered by the research personnel at the practice. Therefore, oncology 
practices with numerous CTEP IDs were grouped under one identification number to 
avoid duplication. Addresses for the clinical trial locations were linked to oncology 
practices and verified by Georgia Cancer Trials database, Georgia CORE portal, site 
locations, and/ or the oncology practices’ official website. Addresses gathered in the 
study reflect the physical street addresses for clinical trial locations, because P.O. boxes 
cannot be geocoded. Suite numbers were also included in the point data.  
In an effort to ensure accuracy, a report was sent to cancer clinical trials locations 
in January 2007 to verify that their sites were accurately reflected in the database report. 
Upon the dissemination of this report, the clinical trial information was updated for each 
responding location. As a part of the update, studies from the Accelerated Community 
Oncology Research Network (ACORN) were also added to the cancer clinical trial 
listings. Before the update, approximately 50 percent of the ACORN studies were not 
found in the Georgia Cancer Trials database. These trials were then added to Georgia 
Cancer Trials, as a result of this study. It is important to note that the Georgia Cancer 
includes approximately 95% of all cancer clinical trials in the state.  
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A second data collection and verification process was conducted from March 8, 
2007 to March 19, 2007. During this process, trials were updated from an additional 
report requested from the national TrialCheck database. Trials from this data collection 
period were added to the initial Microsoft excel spreadsheet that was compiled in 
January. Duplicates and other internal listing problems involving oncology practices were 
identified in this stage and can be found in the limitations section of the discussion 
chapter.  
The next step involved planning the analysis for the study. In order to view the 
number of cancer clinical trials in Georgia, the information had to be changed to a format 
acceptable by the ArcMap application in ArcGIS. After all corrections regarding 
duplication of oncology practice were made, the excel spreadsheet was sent to the Office 
of Health Information and Policy (under the Georgia DHR, Division of Public Health) to 
be geocoded. The plan for analysis also consisted of collecting data in various formats to 
create five sets of maps: 1) a general map of the number of cancer trials offered by 
county, 2) a map of the number of trials by county and the incidence rates by major 
cancer type, 3) a map of the ratios of cancer trials available to the number of new cancer 
patients, 4) a map of the number of trials by county and the incidence rates of African 
American patients by major cancer type, and 5) a map of the number of trials by county 
and the mortality rates by major cancer type.  
It is important to distinguish that there are two common models used to represent 
geographic data: the vector data model and the raster data model. This study used the 
vector data model. Objects in this study are represented by either a point or a polygon 
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feature with well-defined boundaries, as a feature class. A feature class consists of a 
collection of geographic entities with the same geometry type (such as point, line, or 
polygon), the same attributes, and the same spatial reference. Feature classes can either 
stand alone within a geodatabase or be contained within shapefiles, coverages, or other 
feature datasets. Feature classes also allow homogeneous features to be grouped into a 
single unit for data storage purposes. Feature boundaries are defined by x,y coordinate 
pairs. X, Y coordinates are a pair of values that represents the distance from an origin 
(0,0) along two axes, a horizontal axis (x) representing east-west, and a vertical axis (y) 
representing north-south. On a map, x,y coordinates are used to represent features at the 
location they are found on the earth's spherical surface. Points are generally defined by a 
single x,y coordinate pair while polygons are defined by lines that close to form polygon 
boundaries (Rushton 2006). The geocoded listing of Georgia cancer clinical trials 
included these coordinates as point data.  
 
Preparation of Additional Spreadsheets for Data Analysis 
The next step was to prepare the geocoded data into spreadsheets that would later 
be joined with the GIS county shapefile. Much of the preparation was done in the initial 
spreadsheet. However, that data required further manipulation upon receipt in order to 
tailor the information for the various types of maps. In order for the information to 
translate into a readable file, the information needed to be saved as a delimited text file. 
In addition, the data had to be joined with the existing shapefile or a new shapefile had to 
be created. In this study, data was both joined to the Georgia shapefile map and 
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additional shapefiles were created to view data. This required the creation of numerous 
spreadsheets. A general spreadsheet listing the 159 counties in Georgia were compiled 
with the heading “County Name” in order to match the one-to-one relationship needed to 
join the same information with the county shapefile, which was also listed by county 
name. Then, the number of trials in each county was paired with the corresponding 
county name. An additional spreadsheet was created to list the number of trials in each 
county by major cancer type: breast, colorectal, lung and prostate. Data retrieved for this 
spreadsheet included: county name, number of trials, and major cancer type. The 
spreadsheet was saved as a delimited text file to ensure readability in the ArcMap 
application. 
Next, two spreadsheets were combined. The first spreadsheet consisted of a listing 
of cancer clinical trial locations across Georgia with the name of the institution, county, 
and number of trials offered. Counties were labeled and identified for each cancer clinical 
trial listing using the zip codes in the address of the institutions where clinical trials were 
located. The county information was paired with the corresponding trial location and 
verified using the U.S. Census website. Then, the second spreadsheet was created so that 
the point data (all cancer clinical trial listings in the state) could be joined. In order to do 
the second spreadsheet, the attribute table for the county shape file was referenced. Each 
county was listed in the second spreadsheet in the same format used in the attribute table.  
Additional spreadsheets were created utilizing cancer incidence and mortality 
rates provided by the Georgia Comprehensive Cancer Registry. Each spreadsheet 
contained information regarding county name and the corresponding incidence rates for 
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each of the major cancer types. This was also done for African American cancer 
incidence by major cancer type as well as mortality rates for the entire Georgia 
population. After these spreadsheets were created, the data was saved as a delimited text 
file, in preparation for joining with the county shapefile data.  
 
Conversion of point data into a shapefile 
Because the information in this study was collected and geocoded as point data, 
the information had to be converted into a shapefile of the trial locations in order to view 
over patterns of incidence and mortality rates. A shapefile consists of vector data storage 
in a format for storing the location, shape, and attributes of geographic features. A 
shapefile is stored in a set of related files and contains one feature class. A single 
shapefile generally contains at least three main files, and as many as eight. 
An additional spreadsheet was required to layer the number of trials over maps 
containing cancer incidence rates for each major cancer type. This was done using the 
geocoded version of the master spreadsheet containing cancer clinical trial listings. The 
data was filtered and sorted by major cancer type and the new spreadsheets were created 
containing information needed to plot trials for each major cancer type. The master 
cancer clinical trial spreadsheet contained a total listing of cancer clinical trials across the 
state; therefore, the data needed to be sorted by major cancer type. Once the data was 
sorted, the information was copied into a separate spreadsheet and labeled as the 
geocoded version by major cancer type (i.e., Breast_Cancer_Clinical_Trials_Geocoded). 
After further analysis, the file had to be reduced to one location in each county in order to 
have one point representing the number of trials per county because there were numerous 
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points in counties with multiple locations. Leaving this issue unaddressed would have 
produced an inaccurate reflection regarding the density of trials. This data was used along 
with the previously described spreadsheets in order to create maps that reflected cancer 
incidence and mortality rates as a base map with the quantities of trials plotted over the 
incidence rates. In an effort to increase accuracy, statistics regarding the frequency of 
trials by county and major cancer type were analyzed in Statistical Package for the Social 
Sciences (SPSS).  
 
Constructing Maps  
The analysis was executed by joining the information gathered in this study to the 
ArcMap application in ArcGIS. A preliminary map showing the point locations was 
performed through the following steps. First, the downloaded county shapefile was added 
to the ArcMap application. Next, the delimited text file containing geocoded Georgia 
cancer clinical trial listing was added as a layer to the Georgia county map file. The file 
appeared as Georgia_Cancer_Clinical_Trial-Listing_4_2_07_Geocoded1.txt in the 
application.  
A join file was created to link the information gathered on the number of trials to 
the ArcMap application. In order to create a join file, the information has to be listed in 
the same sequence as the file in which it will be joined, as seen in figure 3.2. Once the 
tables are joined, the quantities can be displayed. 
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Figure 3.2 Joining Data in ArcView 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, the ArcMap application was used to create a shape file for the number of 
trials. The county information was linked to the shapefile by joining the two tables. Next, 
the symbology screen was access through layer properties and the quantity field was 
accessed through layer properties to view the quantity of trials by graduated color. The 
value field selected was “number_of_trials”, in order to view the number of trials by 
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county. Class breaks were selected with the colors graduating from yellow to orange, as 
seen in figure 3.3.  
 
 
Figure 3.3 Layer Properties Displaying Graduated Colors 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional maps were done in 4 series. The first series was a basic map showing 
county cancer clinical trial listings by major cancer type. This map was constructed 
through the following steps. First the county shape file was added into ArcGIS. Next, the 
data was joined to the spreadsheet join_file2. Then, the layer properties were changed by 
creating quantity stratification and colors for the newly joined data. This was done in the 
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quantities field. The cancer type was selected as the variable and the default setting was 
selected for the number of natural breaks.  
The next series of maps were created to show the cancer incidence as the base 
data with the number of trials displayed as point data with density of cancer trial 
locations shown by graduated symbol. This was done by conducting the following steps. 
First the base map of the county shape file was joined to the delimited text major cancer 
incidence file, previously described. Then, the layer properties were changed to reflect 
the quantities of cancer incidence joined to the county shape file. The color range was 
chosen and 5-6 natural breaks were selected (depending on the cancer type and pattern).  
Next, the data file containing the limited geocoded cancer clinical trial information by 
major cancer type was added. The X, Y data was displayed and the data was exported 
into a shapefile. The data was then added as a separate layer on top of the base map with 
incidence rate. The newly added data was then joined with the delimited text file 
containing the number of trials by county and major cancer type. As previously noted, 
this information only contained the county names listed with the number of trials in each 
county by major cancer type. Next, the layer properties were changed to display the 
quantities of trials by county. Graduated symbols were used to identify the quantity of 
trials available. A separate map was constructed for each of the four major cancer types 
using these steps.  
The next series of maps were constructed to show the distribution of cancer trials 
as it relates to patterns of cancer incidence rates among African American patients in the 
state by major cancer type. This process was similar to the previously described map 
construction. First, the county shapefile was added and joined with the cancer incidence 
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rate join file. Then the geocoded limited file for the major cancer type was added. This 
file was then converted into a new shapefile and layer. Next, the quantity distribution 
colors were developed in the layer properties.  
The final series of maps displayed the number of trials by mortality rates to reveal 
if trials were available in counties with the highest rates of death. The mortality data 
retrieved from the Georgia Comprehensive Cancer Registry was joined with the county 
shapefile in ArcMap. The number of trials was mapped over the chlorepleth map using 
graduated symbols. The next section will examine and present results found in the GIS 
analysis of cancer clinical trial locations in Georgia.
 
 44
 
 
Chapter IV- Results 
This study found that there are 321 cancer clinical trials (see Appendix A) 
currently enrolling in Georgia. Protocols for the four major cancer types accounted for 
42.1 percent of all protocols (see figure 4.1). This study also found that there are 961 
listings of cancer clinical trials in Georgia. The listings of trials include the locations 
where protocols are offered. This study also found that 53 percent of the cancer clinical 
trials offered in Georgia were in the four major cancer types: 23% breast, 10% colorectal, 
14% lung, and 6% prostate (see figure 4.2). This finding was interesting since the “big 
four” cancers account for 58 percent of all cancer diagnosed and 53 percent of all cancer 
deaths. This study found that cancer clinical trials in the four major cancer types did not 
make up half of the cancer trials offered in the state.  
Figure 4.1 Cancer Clinical Trial Protocols in Georgia by Major Cancer Type 
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Figure 4.2 Cancer Clinical Trial Listings in Georgia by Major Cancer Type 
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Results from this study suggest that nearly 80 percent of the trials were treatment 
trials, see table 4.1.  
 
Table 4.1 Types of Cancer Clinical Trial in Georgia 
 
 Type of Trial Number of 
Trials 
Percent 
 Treatment 767 79.8 
  Supportive care 46 4.8 
  Prevention 24 2.5 
  Other 124 12.9 
 Total 961 100.0 
 
 
 
 
Of the 321 protocols found in this study, there were 961 total cancer clinical trials 
offered in the state. It is important to point out that there is a total of 321 cancer trials 
offered in Georgia at approximately 46 sites. The cancer clinical trial listing of 961 
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reflects where the 321 cancer trials are offered. Therefore, the reference to cancer clinical 
trial listings includes the actual locations where trials are being offered, not simply the 
overall number of protocols. Table 4.2 shows the number of cancer clinical trial listings 
by cancer type. Breast cancer trials are the leading type of cancer trial in Georgia, with 
22.8 percent of the 961 listing of total trials; followed by lung (13.7 percent), colorectal 
(13.1 percent), lymphoma (6.7 percent) and prostate (6.2 percent). 
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Table 4.2 Number of Cancer Clinical Trial Listings by Cancer Type 
  
 
Cancer Type Frequency Percent 
 Billiary Tract 1 .1 
 Bladder 3 .3 
 blood 5 .5 
 Blood 23 2.4 
 Bone and soft tissue 3 .3 
 Brain 20 2.1 
 Breast 219 22.8 
  Cervix 10 1.0 
  Colorectal 97 10.1 
  Esophageal 13 1.4 
  Gallbladder 8 .8 
  Gastrointestinal 23 2.4 
  Genitourinary 4 .4 
  Gynecologic 6 .6 
  Head and Neck 38 4.0 
  Kidney 18 1.9 
  Leukemia 57 5.9 
  Liver 3 .3 
  Lung 132 13.7 
  Lymphoma 64 6.7 
  Melanoma 35 3.6 
  Multiple Myeloma 9 .9 
  Myeloma 24 2.5 
  other 28 2.9 
  Other 2 .2 
  Ovarian 25 2.6 
  Pancreas 9 .9 
  Prostate 60 6.2 
  skin (non-melanoma) 9 .9 
  Uterine 12 1.2 
  Vagina 1 .1 
  Total 961 100.0 
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Cancer clinical trials were found in 15 counties across 24 cities. A complete 
listing of cancer clinical trial listings by county can be found in table 4.3. 
 
Table 4.3 Cancer Clinical Trial Listing by County 
  
 
 County Number of  
Cancer Trials 
Percent 
 Bibb 44 4.6 
  Chatham 121 12.6 
  Clarke 17 1.8 
  Clayton 37 3.9 
  Cobb 96 10.0 
  DeKalb 227 23.6 
  Dougherty 24 2.5 
  Floyd 7 .7 
  Fulton 131 13.6 
  Gwinnett 42 4.4 
  Hall 47 4.9 
  Lowndes 26 2.7 
  Muscogee 33 3.4 
  Richmond 105 10.9 
  Spalding 4 .4 
  Total 961 100.0 
 
 
 
 
In this study, trials were found at 46 sites across the state (see Appendix B). This 
study also found that the majority of cancer clinical trials in Georgia were located in 
metro-Atlanta counties. Table 4.3 shows that nearly 24 percent of all cancer trial listings 
were found in DeKalb County. The number of trials varied outside of the metro-Atlanta 
counties from 7 to 121 trials. There were also a greater number of trials in counties with 
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medical schools. This study found that 55.8 percent of all cancer clinical trial listings 
were located in metro Atlanta counties.  
 
 
Table 4.4 Number of Cancer Clinical Trials by Major Cancer Type and County 
 
County Breast trials Colorectal trials Lung trials Prostate trials 
Bibb 11 2 6 1 
Chatham 21 16 17 6 
Clarke 6 2 4 1 
Clayton 9 2 4 1 
Cobb 28 10 17 2 
DeKalb 32 24 25 15 
Dougherty 5 3 2 1 
Floyd 1 0 3 0 
Fulton 33 12 18 11 
Gwinnett 10 5 9 1 
Hall 15 2 5 6 
Lowndes 5 3 5 1 
Muscogee 10 5 3 2 
Richmond 31 6 13 12 
Spalding 2 1 0 0 
 
 
Findings from this study show that the majority of cancer clinical trials were 
located in Fulton, Richmond, Cobb, Chatham and DeKalb counties. It is interesting that 
the metro Atlanta counties and counties with University medical centers have the 
majority of the trials in the state. Fulton, DeKalb, and Cobb counties are located in metro 
Atlanta. Richmond and Chatham counties have University medical centers, Medical 
College of Georgia and Mercer University School of Medicine, respectively. As seen in 
table 4.4, these counties also tend to lead the state in the most trials in the major cancer 
types.  
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The following map contains a geographic representation of cancer clinical trials in the 
state by listing.  
 
Figure 4.3 
Total Number of Cancer Clinical Trial Listings in Georgia by County 
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Figure 4.3 exhibits the nature of cancer clinical trial distribution across the state. 
Generally, color-coded distribution is only utilized to show rates or ratios; however, for 
illustration purposes, this distribution is shown to give a basic view of trial quantity 
distribution throughout the state. DeKalb County has the largest density of cancer clinical 
trials, followed by Fulton, Chatham and Richmond counties. The following map shows 
the distribution of breast cancer clinical trials in the state. The highest densities of trials 
are offered in metro Atlanta counties. 
 
Figure 4.4 
Breast Cancer Trial Listings in Georgia, by County 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
The following map, Figure 4.5, shows the distribution of colorectal cancer clinical 
trials in the state. Most of the colorectal cancer trials offered in Georgia are also in metro 
Atlanta. DeKalb County has the largest density of colorectal cancer trials of any county 
in the state. This is partly due to the Winship Cancer Institute at Emory University.  
Figure 4.5 
Colorectal Cancer Clinical Trial Listings in Georgia, by County 
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Figure 4.6 
Lung Cancer Clinical Trial Listings in Georgia, by County 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.6 shows the basic distribution of lung cancer clinical trials in the state. 
The largest number of trials appears mainly in metro Atlanta counties, with the exception 
of Chatham County.   
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Figure 4.7 
Prostate Cancer Clinical Trials in Georgia by County 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A basic distribution analysis of the prostate cancer clinical trials in the state shows 
that the largest quantity of trials in DeKalb County, followed by Fulton and Richmond 
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counties. The next series of maps will display cancer incidence rates by major cancer 
types and the number of trials by county.  
 
 
 
 
Figure 4.8 
Breast Cancer Incidence Rates (1999-2003), Number of Breast Cancer Trials in 
Georgia by County 
 
-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The map above shows the distribution of breast cancer incidence rates in the state 
as the base map. In addition, the numbers of breast cancer clinical trials are plotted over 
 56
the incidence rates to view where the breast cancer trials are in relation to the rates of 
new breast cancer cases. The darker pink color indicates a higher breast cancer incidence 
rate while larger densities of trials are indicated by graduated circular symbols. This 
study found that of the 11 counties with the highest rates of breast cancer incidence, only 
one had cancer clinical trials available: Clarke county (see table 4.5) 
 
Table 4.5. Presence of Cancer Trials in Georgia Counties with Highest Level Breast 
Cancer Incidence 
 
County Breast Cancer 
Incidence 
Rate 
Presence of 
Breast Cancer 
Clinical Trials 
Schley 202.0 No 
Ben Hill 158.3 No 
Pickens 156.1 No 
Calhoun 151.5 No 
White 148.3 No 
Lumpkin 147.5 No 
Cherokee 144.3 No 
Oconee 143.2 No 
Clarke 142.6 Yes 
Lanier 141.1 No 
Rockdale 140.7 No 
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Figure 4.9  
Colorectal Cancer Incidence Rates (1999-2003), Number of Colorectal Cancer 
Trials in Georgia by County 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
This study found that 13 counties in Georgia have colorectal cancer clinical trials 
available. The largest quantity of trials is indicated by a larger circle in figure 4.9. This 
figure reveals the number of colorectal trials available in each county layered over the 
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colorectal cancer incidence rates. The findings suggest that the counties with the highest 
incidence rates of colorectal cancer have no cancer trials available in those counties. A 
large number of the colorectal trials are located in the metro Atlanta counties where the 
colorectal cancer incidence rates are lower.  
Table 4.6 Presence of Cancer Trials in Georgia Counties with Highest Level 
Colorectal Cancer Incidence 
 
County Colorectal 
Cancer 
Incidence 
Rate 
Presence of 
Colorectal 
Cancer 
Clinical Trials 
Jasper 87.3 No 
Terrell 86.6 No 
Marion 77.8 No 
Taylor 77.8 No 
Hancock 76.1 No 
Calhoun 73.3 No 
Bacon 71.0 No 
Lamar 70.9 No 
Wilkes 69.6 No 
Stewart 68.6 No 
 
 
 Calhoun and Lanier counties both have the highest incidence rates of breast and 
colorectal cancer and neither have trials available. In addition, there are limited trials in 
proximity to these counties.  
Figure 4.10 shows the lung cancer incidence rates in Georgia with the number of 
trials. Findings were similar to the disparities found in the figure 4.9.  Counties with the 
largest rates of new lung cancer cases have no lung cancer trials available. 
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Figure 4.10 Lung Cancer Incidence Rates (1999-2003), Number of Lung Cancer 
Trials in Georgia by County 
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Table 4.7 Presence of Cancer Trials in Georgia Counties with Highest Level Lung 
Cancer Incidence 
 
County Lung Cancer 
Incidence 
Rate 
Presence of 
Lung Cancer 
Clinical 
Trials 
Lanier 129.0 No 
Quitman 122.9 No 
Ben Hill 122.7 No 
Murray 116.1 No 
Terrell 113.2 No 
Clinch 111.7 No 
Polk 109.6 No 
Wilcox 107.3 No 
 
 
 Lanier County appears again as one of the counties with the highest levels of lung 
cancer incidence and yet they have no cancer clinical trials available. Appendix C shows 
the map with Georgia counties labeled.  
 An analysis of the number of prostate cancer clinical trials by incidence rates 
revealed that 13 of the 159 counties in Georgia offer prostate cancer trials, as seen in 
figure 4.11. Counties with the highest burden of prostate cancer had no prostate cancer 
trials available. Consequently, trials available in neighboring counties were scant. This 
study also found that the number of prostate cancer trials available across the state was 
substantially lower compared to the number of breast, colorectal, and lung cancer trials.   
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Figure 4.11  
Prostate Cancer Incidence Rates (1999-2003), Number of Prostate Cancer Trials in 
Georgia by County 
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Table 4.8 Presence of Cancer Trials in Georgia Counties with Highest Level 
Prostate Cancer Incidence 
 
County Prostate 
Cancer 
Incidence 
Rate 
Presence of 
Prostate 
Cancer 
Clinical 
Trials 
Calhoun 382.4 No 
Thomas 261.8 No 
Terrell 254.6 No 
Mitchell 249.0 No 
Dooly 247.9 No 
 
 
 
 It is interesting to note that the highest rates of new prostate cancer cases are 
largely comprised in South Georgia. Yet, these counties have no prostate cancer trials 
available. Table 4.8 displays the five counties with the highest rates of prostate cancer 
incidence. These findings indicate a serious public health issue, particularly since there is 
only a combined five prostate cancer trials in the entire southwest corner of the state. This 
also leads to a question regarding why there are no more than 15 trials found in one 
county, compared to the number of trials available for breast, colorectal and lung cancers.  
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Figure 4.12 
Breast Cancer Incidence Rates in African Americans (1999-2003), Number of 
Breast Cancer Trials in Georgia by County  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 shows the rates of new breast cancer cases in African American 
women in the state. This analysis revealed that 2 of the 9 counties with the highest breast 
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cancer incidence rates for African American women had breast cancer trials, Clarke and 
Hall counties. The largest quantities of trials were found in Fulton, DeKalb, Cobb, and 
Richmond.  
 
Figure 4.13 
Colorectal Cancer Incidence Rates in African Americans (1999-2003), Number of 
Colorectal Cancer Trials in Georgia by County  
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Figure 4.13 shows the colorectal cancer incidence in the African American 
population by county and the number of trials available.  Counties with the highest rates 
of colorectal cancer incidence in African Americans, there were no trials present. 
However, in counties with moderately high colorectal cancer incidence rates for this 
population, trials were available in 5 out of 17 counties. 
 An analysis of lung cancer incidence rates in African Americans and lung trials 
available to them found no trials available in the counties with the highest incidence 
rates, as seen in figure 4.14. In addition, no more than six trials were available in counties 
with the second highest level of lung cancer incidence in the African American 
population. Furthermore, the highest quantities of trials were found in counties with 
moderate lung cancer incidence rates. Two-thirds of the counties with the largest 
quantities of trials were located in metro Atlanta.  
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Figure 4.14 
Lung Cancer Incidence Rates in African Americans (1999-2003), Number of Lung 
Cancer Trials in Georgia by County  
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Figure 4.15 displays the number of prostate cancer trials available by county and 
prostate cancer incidence rates in the African American population. This study found that 
there were no trials available in counties with the highest prostate cancer incidence rates. 
In addition, the counties with the second highest levels of prostate cancer incidence rates 
in this population had a single trial in 1 out of 26 counties. 
 
Figure 4.15  
Prostate Cancer Incidence Rates in African Americans (1999-2003), Number of 
Prostate Cancer Trials in Georgia by County   
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 The next series of maps will display cancer mortality rates by major cancer type 
and the number of trials by county.  
 
 
Figure 4.16 
Breast Cancer Mortality Rates (1999-2003), Number of Breast Cancer Trials by 
County in Georgia by County  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.16 depicts the number of breast cancer trials by mortality rates of the 
disease. There were no trials found in counties with the highest rates of breast cancer 
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deaths. However, of the counties offering breast cancer trials, the largest number of trials 
was found in counties with the second highest mortality rates.  
 
 
Table 4.9 Presence of Cancer Trials in Georgia Counties with Highest Level Breast 
Cancer Mortality Rates 
 
County Breast  Cancer 
Incidence Rate 
Presence of 
Breast Cancer 
Clinical Trials 
Butts 44.4 No 
Stephens 43.2 No 
Pickens 39.5 No 
Polk 36.1 No 
McDuffie 35.2 No 
 
 
 
 This study also analyzed the number of colorectal cancer trials by the rates of 
colorectal cancer deaths, as seen in figure 4.17. Results show that there were no trials 
available in counties with the highest mortality rates. In addition, there were no colorectal 
cancer trials found in counties with the second highest rates of colorectal cancer deaths. 
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Figure 4.17 
Colorectal Cancer Mortality Rates (1999-2003), Number of Colorectal Cancer 
Trials in Georgia by County  
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Table 4.10 Presence of Cancer Trials in Georgia Counties with Highest Level 
Colorectal Cancer Mortality Rates 
 
County Colorectal  
Cancer 
Mortality Rate 
Presence of 
Colorectal Cancer 
Clinical Trials 
Terrell 53.4 No 
Screven 34.2 No 
Ben Hill 32.1 No 
 
 
Table 4.10 shows that there were no colorectal cancer clinical trials available in 
counties with the highest rates of mortality for the disease. Terrell, Screven and Ben Hill 
counties were the top three counties with the highest colorectal cancer mortality rates in 
Georgia.  
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Figure 4.18 
Lung Cancer Mortality Rates (1999-2003), Number of Lung Cancer Trials in 
Georgia by County  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.18 shows the number of lung cancer trials and mortality rates of lung 
cancer by county. Results reveal that the counties with the highest rates of mortality have 
no cancer clinical trials. Also, the counties with the second highest levels of lung cancer 
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mortality have trials available in 0 out of the 35 counties with mortality rates between 
84.1 and 109.2 per 100,000, as seen in table 4.11.    
Table 4.11 Presence of Cancer Trials in Georgia Counties with Highest Level Lung 
Cancer Mortality Rates 
 
 
County Lung Cancer 
Mortality Rate 
Presence of 
Lung Cancer 
Clinical Trials 
Murray 109.2 No 
Ben Hill 108.8 No 
Terrell 102.1 No 
Clinch 97.4 No 
Bleckley 96.3 No 
Walker 88.6 No 
Lanier 88.2 No 
 
 The next map displays the number of prostate cancer clinical trials in the state by 
prostate cancer mortality rates, see figure 4.19. There were no trials found in counties 
with the highest death rates from prostate cancer. However, a substantial number of trials 
were found in counties with the second largest prostate cancer mortality rates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Figure 4.19 
Prostate Cancer Mortality Rates (1999-2003), Number of Prostate Cancer Trials in 
Georgia by County  
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Table 4.12 Presence of Cancer Trials in Georgia Counties with Highest Level 
Prostate Cancer Mortality Rates 
 
County Prostate  Cancer 
Incidence Rate 
Presence of Prostate 
Cancer Clinical Trials 
Burke 73.9 No 
Peach 66.2 No 
Harris 63.1 No 
Brooks 60.2 No 
Mitchell 58.8 No 
Elbert 52.5 No 
Sumpter 51.6 No 
Coffee 51.4 No 
 
 
There were also no cancer clinical trials found in counties with the highest 
prostate cancer mortality rates. This finding is interesting, particularly since the death 
rates for prostate cancer are higher than those of breast and colorectal cancers. Also, 
many of the counties with the highest prostate cancer mortality rates are in Southeast 
Georgia were there are no more than 5 trials in the entire region. 
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Chapter V- Discussion 
Cancer is a serious public health problem across the state of Georgia. In an effort to 
identify potential health disparities regarding cancer clinical trials, an analysis of trials by 
location, cancer type, cancer incidence rates, cancer mortality rates and racial patterns in 
Georgia counties was conducted. To the best of our knowledge, this paper represents the 
first study to examine the number of cancer clinical trial listings across the state of 
Georgia by major cancer type, incidence rates, mortality rates, and geographic 
distribution of racial patterns. Recent studies suggest that location of and distance to 
treatment centers affect a patient’s decision on whether or not to enroll in a clinical trial 
(Celaya et al. 2006). This is important because cancer clinical trial participation is low 
and barriers to cancer clinical trials access should be minimal (Comis 2003). This study 
did not focus on childhood cancer clinical trials because there is a 60 percent accession 
rate of cancer clinical trials in pediatric patients. This is substantially higher than the 
estimated 3 percent of adult cancer patients who participate in clinical trials (NCI 2001).  
In this study, the entire dataset was not found in a central location. Information was 
gathered from various sources, including the Georgia Division of Public Health Office of 
Health and Information Policy, the Georgia Comprehensive Cancer Registry, the Georgia 
Cancer Trials Database, and community oncology practices. These sources provide valid 
data regarding cancer trial locations in Georgia, geographic display of Georgia counties 
and cancer incidence and mortality rates in the state, respectively. The analysis was 
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sconducted using GIS software. GIS provides the means for identifying and displaying 
geographic patterns, thus providing a useful investigation tool for cancer screening, 
mortality and incidence rates. In addition, GIS can be used to examine geospatially-
related questions regarding availability of cancer clinical trials in Georgia.  
This study found that the largest number of cancer clinical trials in Georgia were 
concentrated primarily in metro Atlanta counties. While this data was not directly 
comparable to previous published studies, findings from this study can be used as 
introductory information to further understand cancer clinical trial availability in Georgia. 
Findings from this study also suggest that there are disparities in cancer clinical trial 
access as defined by locations across the state. Tables 4.5-4.12 show that counties with 
the highest rates of incidence and mortality for breast, colorectal, lung and prostate 
cancers have little or no cancer clinical trials available. 
Results from this study are demonstrative of the problems facing cancer clinical trial 
availability (directly) and cancer clinical trial enrollment (indirectly) in Georgia. This 
issue is not unique to Georgia. The nation as a whole suffers from few availability of 
cancer clinical trials for disparate populations (Comis, 2003). Lack of sufficient 
availability of trials has proven to be a barrier to enrollment. This is an important issue 
because cancer clinical trials are crucial in the evaluation of safe and effective new drug 
treatments. Since clinical trials rely on volunteers, it is critical to make trials available 
and accessible to cancer patients. This may reduce disparities regarding treatment options 
and give cancer patients treatment alternatives to a disease perceived often times as a 
death sentence. 
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This study also found that 42.1 percent of the cancer clinical protocols offered in 
Georgia were in the four major cancer types (23% breast, 10% colorectal, 14% lung, and 
6% prostate, see Figure 4.2). This finding raises questions regarding whether 42.1 percent 
of all cancer clinical protocols being in the major four cancers is sufficient, particularly 
since the major cancer types account for 58 percent of all cancer diagnoses and 53 
percent of all cancer deaths (Singh 2005), . This is an important issue because breast, 
colorectal, lung, and prostate cancer protocols did not make up half of the cancer trials 
offered in the state; however, they account for more than half of cancer diagnoses and 
deaths.  
This study also found that the majority of breast and lung cancer ongoing trials were 
in metro Atlanta counties compared to rural counties. As of March 2007, there were only 
15 counties in the state offering cancer clinical trials. This study also found that 55.8 
percent of the trial listings were located in metro Atlanta counties.  This study also found 
that no trials were offered in counties with the highest colorectal, lung and prostate 
cancer incidence rates. In addition, less than six trials were found in counties with the 
highest incidence rates of breast cancer. This is important when answering the question of 
whether cancer clinical trials are adequately available in the state. Findings in this study 
show that the highest distribution of cancer trials by major cancer type appears mostly in 
metro Atlanta counties.  
When investigating the major cancer types by incidence rates and number of trials, it 
is important to study racial disparities. Due to limitations with incidence and mortality 
data available from the Georgia Comprehensive Cancer Registry, the African American 
population was the only racially diverse group analyzed in this study. This study found 
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that no colorectal, lung, and prostate trials were available for African Americans in 
counties with the highest incidence rates. In addition, 2 of the 9 counties with the highest 
breast cancer incidence rates for African American women had trials available. 
Therefore, this study shows that there is a disparity among the African American 
population in Georgia, regarding the number of trials available to new cancer patients. 
This also implies that strategic planning is needed to address the cancer clinical trial 
availability for minority patients in the state.  
This study also found that there were no cancer clinical trials available for counties 
with the highest mortality rates for breast, colorectal, lung and prostate cancers. This 
finding indicates that there are no trials available in counties where patients are dying the 
most. This is disheartening, particularly for counties with the highest breast and prostate 
cancer mortality rates because there were no trials available within 50 mile proximity. 
Generally, disparities in medical care exist in the following populations: minorities, 
rural residents, and the elderly. Since the enactment of the National Institutes of Health’s 
Revitalization Act of 1993, many cancer researchers have place an increased focus on 
recruiting underrepresented populations in clinical trials (McCray 2000). As Georgia 
invests the state-allotted tobacco settlement money in cancer research, it is important to 
leverage these funds to decrease the level of the asymmetry of information regarding 
cancer clinical trial locations and availability. Findings from this study suggest that there 
are not an adequate number of cancer clinical trials available in counties experiencing the 
highest burden of the disease.  
Strengths of this study include that the data was obtained from Georgia’s only state-
specific cancer clinical trial database. This is particularly important since there are 
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various cancer clinical trial registries with different reporting techniques. Having a state-
wide cancer clinical trial database helps with the accuracy of the cancer clinical trial 
listings. The Georgia Cancer Trials database is vital because it details the exact locations 
where cancer trials are offered, which is not the case with the national cancer clinical trial 
database. Oftentimes, clinicaltrials.gov will list the state and cities only, with no 
indication of the actual location of the trial.  
An additional strength of this study is the use of GIS to map cancer clinical trial 
locations. This is particularly helpful since cancer incidence and mortality reporting is 
done using this software. GIS allows more precise plotting of cancer trial locations 
compared to other mapping software. In addition, exact addresses where used in this 
study to increase accuracy of the point data. Also, the information retrieved for the 
Georgia Cancer Trials database was verified with oncology practices across the state to 
ensure accuracy.  
It is important to discuss limitations involved in the study. First, there were 
duplicates found with the Georgia Cancer Trials database. As stated previously, cancer 
clinical trials are required to be registered. Consequently, there is no centralized 
registration database to ensure non-duplicative listings of oncology practices. There were 
numerous inconsistencies found with the way trials were listed by oncology practice/ 
institution. For example, The Medical Center- John B. Amos Cancer Center was listed as 
both “The Medical Center” and as “John B. Amos Cancer Center”. At first glance, it was 
not apparent that this was the same institution. However, after sending the report to the 
site and discussing with their clinical research staff, it was found that this was the same 
 
 81
site and research staff entering the data into the national database was using different 
forms of the organization’s name.  
This type of error was also found at Eisenhower Medical Center, Nancy N. and J. C. 
Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Northside Hospital Cancer 
Center, Medical College of Georgia Cancer Center, and Charles B. Eberhart Cancer 
Center at DeKalb Medical Center. Each location appeared at least twice in the database 
under variations of their true name. These inconsistencies were noted and corrected in the 
Georgia Cancer Trials database as well as the dataset for this study.  
The existence of multiple practices and reporting were also limited this study. Many 
oncology practices have satellite clinics that are not currently being captured in the 
national database. For example, Wellstar Health System has numerous satellite facilities. 
All of these facilities may not be listed in the national or Georgia Cancer Trials database. 
This is an issue of user error where the individual entering information at the oncology 
practices does not give all satellite locations and the time of data entry. However, this 
issue does not account for a significant change in the trial listing. Many of the satellite 
locations are in the same counties as the parent institution.  
This study was also limited by the availability of cancer morbidity and mortality data 
available from the Georgia Comprehensive Cancer Registry. The mortality rate for 
African Americans by county was not included in this study due to the lack of data from 
a significant number of counties. Much of the data regarding African American cancer 
mortality rate by county was suppressed. Therefore, the data was not useful to compare 
cancer clinical trial availability as it relates mortality rates of African American patients 
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because mortality rates were not able to be captured (value was less than five) in most of 
the counties.  
Another limitation of the study deals with capturing the cancer clinical trial listings 
by counties. This may limit the study because patients are not confined to participating 
solely in cancer clinical trials offered in their counties of residence. In many cases, 
patients must travel outside of their residing county, and maybe outside of their state, in 
order to enroll in a cancer clinical trial. For example, patients outside of DeKalb County 
may be participating in cancer clinical trials at the Emory Winship Cancer Institute. This 
study may be limited in scope because it assesses whether trials are located in counties 
with the highest disease burden and does not account for patient travel from other 
counties, mainly because data regarding patient accrual and travel distance was not 
available for this study.  
The lack of data regarding the number of patients enrolled in cancer clinical trials 
gives rise to another limitation of this study. This information would provide further 
indication of where most patients enroll and how far the travel to participate in a cancer 
clinical trial. There have been discussions from the Georgia Center for Oncology 
Research and Education regarding the feasibility of collecting patient accrual data. 
Collection of this data is important to achieve the objective 6.1 of the Institute of 
Medicine Report on Assessing the Quality of Cancer Care in Georgia (Eden and Simone 
2005).  
Because travel distance to the clinical trial location is a major factor in participation, 
particularly in minority communities, it is important to have some baseline information 
regarding cancer clinical trial availability at the county level.  Joining the number of trials 
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by county with the cancer incidence and mortality rates may limit the scope of this paper. 
More data should be collected regarding how far cancer patients travel to participate in 
cancer clinical trials in Georgia to better understand whether an appropriate number of 
cancer clinical trials are being offered in the state at the local level.  
It is important to capture information regarding how many cancer clinical trials is 
considered sufficient, particularly in rural counties. This study found that counties outside 
of the metro area had substantially less trials than metro Atlanta counties. This is 
important because protocol availability is limited to participating sites. This is 
particularly important because there is a large area in the southeast portion of the state 
that has no cancer clinical trials offered. This study found that Chatham County was the 
closest county in that region with a large density of trials. It was also the county with the 
largest density of trials outside of metro Atlanta counties. However, this raises the 
question of whether or not patients in this area would be willing to drive to Chatham 
County to participate in a cancer clinical trial.  
It is the recommendation of this paper that Georgia invest resources to collect data 
regarding how many cancer patients participate in cancer clinical trials and where cancer 
clinical trial participation is the highest. This would not only help to assess the quality of 
clinical cancer care in the state, but it will also give the medical community pertinent 
information about whether there are enough trials available for those who wish to 
participate. This information would also indicate the type of trials that accrue patients and 
which oncology practices conduct the most clinical research. This data can be compared 
with cancer morbidity and mortality data to see if the cancer clinical trials that accrue the 
most patients, actually reflect the burden of cancer in the state. Furthermore, it would 
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answer whether patients are being accrued to studies that are in the “Big Four” cancer 
types: breast, colorectal, lung, and prostate cancers.  
It is hopeful that findings from this study will assist with determining disparities in 
cancer clinical trial availability and state cancer planning. This study should spark 
interest in and resources towards securing a strategic approach to the offering of cancer 
clinical research in Georgia.  It should also trigger discussion regarding the following 
three questions: 
1. What do we want the cancer clinical trial picture to look like in 2, 5, 10 
years? 
2. What is an adequate number of cancer clinical trials, by a specific parameter? 
3. How will we secure strategic placement of cancer clinical trials across 
Georgia? 
 
With an estimated 36,000 Georgians diagnosed with cancer annually (Singh et al. 
2005), this analysis should help define baseline data and help guide future cancer 
research planning. The purpose of this study was to determine the density of cancer 
clinical trial locations within the state. This study found that being a resident of metro-
Atlanta or living in a county with a medical schools present increased the probability of 
cancer clinical trial availability. However, more trials were found to be available per 
cancer patient outside of metro Atlanta counties.  
The social implications of this study are important in ensuring the availability of and 
access to cancer clinical trials across the state. This is particularly critical in minority 
populations who are generally more susceptible to cancer. African American men and 
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women have an increased likelihood of developing cancer in their lifetime (Singh et al 
2005). This study found that, in Georgia, disparities exist in both cancer morbidity and 
cancer clinical trial availability. Density of cancer clinical trials is higher in metro-
Atlanta. Therefore, areas located outside of metro-Atlanta have unequal distribution of 
cancer trials. The cancer burden is higher in minorities and rural patients. In addition, 
counties with medical schools had an increased chance of having a substantial number of 
cancer clinical trials compared with other non metro counties.  
It is important to note that there is an Atlanta Community Clinical Oncology 
Program (Atlanta CCOP) that was initiated in 1993 by NCI to provide more access to 
cancer clinical trials among community oncology practices in the Atlanta area. Saint 
Joseph’s Healthcare of Atlanta is the parent institution for the Atlanta Regional CCOP 
(http://www.atlantaccop.org/). There are eight institutions involved with Atlanta Regional 
CCOP: Saint Joseph’s Hospital of Atlanta, Charles B. Eberhart Cancer Center at DeKalb 
Medical Center, Northside Hospital, Piedmont Hospital, Wellstar Cobb Hospital, 
Kennestone Cancer Center at Wellstar Kennestone Hospital, Southern Regional Medical 
Center, and Gwinnett Health System. CCOP protocols are offered at all of the CCOP 
locations. This increases the availability of cancer clinical trials in the previously listed 
Atlanta oncology practices. These protocols may be present in community practices 
across the state, but because those practices are not a part of the Atlanta Regional CCOP, 
it is not guaranteed that the CCOP trials will be available.  
In an effort to make more trials available across the state, it is the recommendation of 
this paper that non-Metro Atlanta oncology practices be allowed to participate in Atlanta 
Regional CCOP trials. This would ensure that smaller practices that wish to increase their 
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offerings of cancer clinical trials would easily be able to do so. In addition, this would 
instantly increase the cancer clinical trial listings across Georgia. This type of schema is 
similar to businesses that franchise their organizations in an effort to reach a wider 
audience to increase profits. Increasing access to Atlanta Regional CCOP trials in non- 
Metro Atlanta areas would help to make trials available to a larger number of cancer 
patients in an effort to decrease disparities and adverse outcomes. This may require a 
statewide collaboration using members of the Georgia CORE network and partnerships 
with the Atlanta Regional CCOP. 
Furthermore, this study recommends that Georgia focuses on a strategic approach to 
the placement or dispersal of cancer clinical trials. It is important for patients to have a 
variety of options regarding cancer clinical trials. This may require investing resources in 
pilot programs for clinical research in counties which showed minimal cancer trial 
availability, particularly in Floyd, Lowndes and Muscogee counties. 
There are an estimated 5,000 trials offered in the United States (NCI 2001). Though 
this study found that Georgia has 321 protocols, totaling 961 listings, a large portion of 
the total trials were located in metro-Atlanta counties. Therefore, researchers, public 
health officials, and cancer advocates should secure equitable access of cancer trials 
across the state. Findings of the study showed that there are disparities in the availability 
of cancer clinical trials across the state, particularly in rural and non Metro-Atlanta areas. 
This is particularly important since this study found that counties with the greatest 
disease burden had no trials available. Therefore, a concerted effort should be made to 
ensure that trials are available in or near counties with the highest cancer incidence and 
mortality rates. 
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It is also the recommendation of this study that oncologists and public health officials 
in the state adopt a plan to address clinical trial disparities, specifically targeting counties 
outside of the metro-Atlanta area. First, officials should ensure an adequate number of 
trials be available across the state by increasing the number of trials available at existing 
sites. This may require a fund source for increased staffing capacity.  
Results from this study showed that the cancer clinical trial listings across counties 
varied from 4 to 227. The baseline data found in this study should provide the oncology 
community and public health officials with information about the state of cancer clinical 
trials in the state and where the researchers want the state to be in the next 5,10, and 15 
years. This is particularly important in counties that lack the presence in the metro area as 
well as counties that lack medical schools. This is a huge issue because it implies that 
there is disproportionate access to cancer trials. 
In conclusion, this study set out to answer three important questions regarding cancer 
clinical research in Georgia: 1) what is the geographic distribution of cancer clinical trials 
in Georgia, 2) are cancer clinical trials available in counties with the highest burden of 
disease, and 3) is there a disparity in cancer clinical trial locations as it relates to racial 
pattern? Findings from this study showed that in March 2007, there were 321 protocols 
for cancer clinical trials offered at 46 sites across the state. This study also suggests that 
there were no trials available in counties with the highest cancer incidence and mortality 
rates for colorectal, lung and prostate cancers. Thirdly, there were similar findings when 
viewing the number of trials available for African American cancer patients, by incidence 
rate.  
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This study addresses the issue of information asymmetry by providing the number of 
cancer clinical trial locations in Georgia and identifying disparities associated with cancer 
trial locations and where the disease burden is greatest. This study also shows the 
importance of having baseline information to display the state of cancer clinical research. 
As the second leading cause of mortality in the state, billions of dollars have been 
invested in cancer clinical research. It is important to invest resources in reducing this 
disproportionate gradient of information and cancer disparities across the state.  
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Appendix A 
 
Georgia Cancer Clinical Trial Protocols 
 
1.  #123 
2.  0230B 
3.  0405-2006 
4.  0414-2006 
5.  0466-1998 
6.  0533-2003 
7.  0596-2004 
8.  0693-2002 
9.  1 R01 MH071580-01A2 
10.  10105 
11.  1048-2001 
12.  11800 
13.  11961 
14.  1341-2004 
15.  1342-2004 
16.  136 
17.  150106 
18.  174-2004 
19.  198-2002 
20.  20040213 
21.  2005_010 
22.  26866138CAN2007 
23.  3160A4-200 
24.  3410 
25.  553 
26.  60104 
27.  70103 
28.  9665 
29.  9760 
30.  Å6-003 
31.  A8501001 
32.  ACORN AEJSINS0601 
33.  ACORN ALJBMM0502 
34.  ACORN ALSSNBC0401 
35.  ACORN ALSSOPR0501 
36.  ACORN B9E-US-S377 
37.  ACORN H3E-MC-JMEN 
38.  ACORN H6Q-MC-JCBJ(b) 
39.  ACORN INS0601 
40.  ACOSOG-Z1031 
41.  ACOSOG-Z6041 
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42.  ACOSOG-Z9001 
43.  ACRIN-6673 
44.  AMC-038 
45.  AMD3100-2112 
46.  American BioSciences-CA023 
47.  Amgen-20060136 
48.  AMGEN A147 
49.  AMGEN A244 
50.  ANTISOMA-AS1404-203 
51.  AOI-206 
52.  AOI-208 
53.  AOI-211 
54.  AOI-215 
55.  APP-C2006-01 
56.  AVF3430n 
57.  AVF3671g 
58.  AVF3693g 
59.  AVF3694g 
60.  AVF3991n 
61.  Bayer-11961 
62.  BIOCRYST-BCX1777-T-04-201 
63.  BIOVEST-BV301 
64.  BMS-CA183001 
65.  BMTCTN-0102 
66.  BMTCTN-0201 
67.  BRE 0303 
68.  CA183-002 
69.  CA225251 
70.  CALGB-100104 
71.  CALGB-10105 
72.  CALGB-20203 
73.  CALGB-30406 
74.  CALGB-30407 
75.  CALGB-40101 
76.  CALGB-49907 
77.  CALGB-50203 
78.  CALGB-50303 
79.  CALGB-70301 
80.  CALGB-80101 
81.  CALGB-90202 
82.  CALGB-90401 
83.  CALGB-9665 
84.  CALGB-C80405 
85.  CAMN107A2109 
86.  CAN-NCIC-LY.12 
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87.  CAN-NCIC-MA.27B 
88.  CAN-NCIC-MA27 
89.  CAN-NCIC-MAP3 
90.  CAN-NCIC-MY10 
91.  CB01-202 
92.  CCBX001-049 
93.  CCCGHS-NCI-T98-0085 
94.  CCCWFU-71103 
95.  CCCWFU-98301 
96.  CDC-NCCDPHP-R-01-PH-000018 
97.  CG53135-CLN-12 
98.  CICL670AUS03 
99.  CLTR0105-201 
100. CMM-95079 
101. CONCEPT L-9444 
102. CP02-0452 
103. CP02-0555 
104. CR008566 
105. CSU-GCC-161 
106. CTKI258A2103 
107. CTSU E2805 
108. CYC202-06-14 (A1) 
109. CZOL446 EUS24 
110. CZOL446E2352 
111. CZOL446GUS63 
112. D9902B 
113. DFCI-04006 
114. DOCET_L_00712 
115. DUMC03 
116. E1Y03 
117. ECOG-1697 
118. ECOG-1900 
119. ECOG-1C99 
120. ECOG-1Y97 
121. ECOG-2602 
122. ECOG-5501 
123. ECOG-5597 
124. ECOG-5998 
125. ECOG-E1302 
126. ECOG-E1B03 
127. ECOG-E1F03 
128. ECOG-E2204 
129. ECOG-E2501 
130. ECOG-E2603 
131. ECOG-E2805 
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132. ECOG-E2902 
133. ECOG-E2Z04 
134. ECOG-E3204 
135. ECOG-E3803 
136. ECOG-E3903 
137. ECOG-E4203 
138. ECOG-E4402 
139. ECOG-E4903 
140. ECOG-E5202 
141. ECOG-E5204 
142. ECOG-E6202 
143. ECOG-E6501 
144. ECOG-PACCT-1 
145. ECOG-S9346 
146. ECOG PACCT-1 
147. Eli Lilly B9E-US-S182 
148. Eli Lilly B9E-US-S377 
149. Eli Lilly H6Q-MC-JCBJ 
150. ENRICH Study 
151. EU312-97 
152. EU822-03 
153. FCCC-FCRB-04-003-P 
154. FHCRC-1938.00 
155. FHCRC-1992.00 
156. FHCRC-2054.00 
157. G-0029 
158. G-0034 
159. GOG-0130E 
160. GOG-0136 
161. GOG-0146O 
162. GOG-0146Q 
163. GOG-0187 
164. GOG-0188 
165. GOG-0192 
166. GOG-0198 
167. GOG-0199 
168. GOG-0204 
169. GOG-0206 
170. GOG-0209 
171. GOG-0210 
172. GOG-0211 
173. GOG-0212 
174. GOG-0218 
175. GOG-0219 
176. GOG-0222 
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177. GOG-0227c 
178. GOG-0232B 
179. GOG-173 
180. GOG-174 
181. GOG-175 
182. GSK-EGF103659 
183. GSK-EGF30008 
184. GV-001.004 
185. H57/CCH420680-05 
186. HN 0501 
187. Hx-CD4-110 
188. IBCSG-24-02 
189. IBCSG-25-02 
190. IBCSG-27-02 
191. IRB3 021-2005 
192. JHOC-J0252 
193. JNJ-26866138-LYM-3001 
194. KOS-202/NO18401 
195. LCCC 0512 
196. M05-780 
197. MCC-0203 
198. MCC-0502 
199. MCSP-00-0107 
200. MDA-ID-00156 
201. MDX010-20 
202. MGH-000084 
203. MILLEN.EVERECT 
204. NABTT-0306 
205. NABTT-0307 
206. NABTT-0401 
207. NABTT-0404 
208. NABTT-0501 
209. NABTT-0503 
210. NABTT-0504 
211. NABTT-2201 
212. NABTT-9806 
213. NABTT-9902 
214. NABTT-9910 
215. NCCTG-N0147 
216. NCCTG-N0177 
217. NCCTG-N01C5 
218. NCCTG-N02C4 
219. NCCTG-N0434 
220. NCCTG-N0437 
221. NCCTG-N04C7 
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222. NCCTG-N9943 
223. NCI-04-C-0001 
224. NCI-06-C-0043 
225. NCI-7306 
226. NCI-92-C-0137M 
227. Novacea 011-007 
228. Novacea 011-015 
229. NSABP-B-36 
230. NSABP-B-37 
231. NSABP-B-38 
232. NSABP-B-39 
233. NSABP-B-40 
234. NSABP-B-42 
235. NSABP-C-09 
236. NSABP-C-10 
237. NSABP-R-04 
238. NTI-0303 
239. NTI 0501 
240. ONCOTHER-20052183 
241. ONCOTHER-MAC001 
242. OSI-774-203 
243. OSI-774-302 
244. OSI3364g 
245. PC B305/02 
246. PC B305/04 
247. Perifosine 212 
248. Perifosine 217 
249. POI-02818 
250. RTOG-0123 
251. RTOG-0212 
252. RTOG-0214 
253. RTOG-0232 
254. RTOG-0233 
255. RTOG-0247 
256. RTOG-0320 
257. RTOG-0421 
258. RTOG-0424 
259. RTOG-0521 
260. RTOG-0522 
261. RTOG-0525 
262. RTOG-L-0117 
263. SEGO_DOXIL_CONS2005 
264. STAN-973 
265. STR 0303 
266. SWOG-8947 
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267. SWOG-9007 
268. SWOG-S0008 
269. SWOG-S0016 
270. SWOG-S0028 
271. SWOG-S0106 
272. SWOG-S0124 
273. SWOG-S0220 
274. SWOG-S0221 
275. SWOG-S0226 
276. SWOG-S0230 
277. SWOG-S0232 
278. SWOG-S0306 
279. SWOG-S0307 
280. SWOG-S0309 
281. SWOG-S0329 
282. SWOG-S0331 
283. SWOG-S0334 
284. SWOG-S0350 
285. SWOG-S0414 
286. SWOG-S0415 
287. SWOG-S0424 
288. SWOG-S0425 
289. SWOG-S0429 
290. SWOG-S0430 
291. SWOG-S0434 
292. SWOG-S0435 
293. SWOG-S0508 
294. SWOG-S0509 
295. SWOG-S0511 
296. SWOG-S0515 
297. SWOG-S0536 
298. SWOG-S9704 
299. SWOG-S9910 
300. SWOG-S9921 
301. SWOG-S9925 
302. SWOG BMT CTN 0102 
303. TG-001 
304. TM-601-002 
305. TRIAD BOI/Muscositis 
306. U2963n 
307. UCLA-0307121-01 
308. UCSD-040749 
309. UMN-2004UC035 
310. VBLT980-04 
311. VSLI-06-ALL 
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312. VU-VICC-HN-0501 
313. WCI-1078-05 
314. WCI-752-02 
315. WCI1950-04 
316. WCI901-04 
317. WCI957-04 
318. WILEX-WX-2003-07-HR 
319. XCYTE-XT004 
320. XL119-001 
321. XT009 
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Appendix B 
 
Cancer Clinical Trial Listing by Institution 
 
Institutions Number 
of trials 
Percent 
 Atlanta Cancer Care - Roswell 8 .8
  Atlanta Cancer Care at St. Joseph 1 .1
  Augusta Oncology Associates - Walton 
Way 
49 5.1
  Blood and Marrow Transplant Group of 
Georgia 
4 .4
  Central Georgia Cancer Care, PC - Macon 12 1.2
  Charles B. Eberhart Cancer Center at 
DeKalb Medical Center 
43 4.5
  Clayton State University 1 .1
  Cobb Memorial Hospital 1 .1
  Columbus Clinic, PC 2 .2
  Curtis & Elizabeth Anderson Cancer 
Institute at Memorial Health University 
Medical Center 
82 8.5
  Eisenhower Army Medical Center 7 .7
  Emory Crawford Long Hospital 10 1.0
  Georgia Cancer Center for Excellence at 
Grady Memorial Hospital 
8 .8
  Georgia Cancer Specialists - Northside 
Office 
1 .1
  Georgia Cancer Specialists - Tucker 5 .5
  Georgia Urology - Atlanta 3 .3
  Gwinnett Medical Center 34 3.5
  Harbin Clinic 7 .7
  Kennesaw State University 1 .1
  Kennestone Cancer Center at Wellstar 
Kennestone Hospital 
38 4.0
  Medical Center of Central Georgia 32 3.3
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  Medical College of Georgia Cancer Center 43 4.5
  Medical Oncology Associates, PC 2 .2
  Morehouse School of Medicine 1 .1
  Mount Vernon Clinical Research, LLC 1 .1
  Nancy N. and J. C. Lewis Cancer and 
Research Pavilion at St. Joseph's/Candler 
37 3.9
  Northeast Georgia Cancer Care, LLC 17 1.8
  Northeast Georgia Medical Center 47 4.9
  Northside Hospital Cancer Center 39 4.1
  Northwest Georgia Oncology Centers, PC - 
Marietta Center 
17 1.8
  Peachtree Hematology and Oncology 
Consultants, P.C. 
11 1.1
  Pearlman Comprehensive Cancer Center 
at South Georgia Medical Center 
26 2.7
  Phoebe Cancer Center at Phoebe Putney 
Memorial Hospital 
24 2.5
  Piedmont Hospital 40 4.2
  Saint Joseph's Hospital of Atlanta 37 3.9
  South Fulton Medical Center 4 .4
  Southeastern Gynecologic Oncology, LLP - 
Northside 
2 .2
  Southern Regional Medical Center 36 3.7
  Spalding Oncology Services 4 .4
  Suburban Hematology-Oncology 
Associates, PC 
8 .8
  Summit Cancer Care 2 .2
  The Medical Center Inc., John B. Amos 
Community Cancer Center 
31 3.2
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  Veterans Affairs Medical Center - Atlanta 
(Decatur) 
21 2.2
  Veterans Affairs Medical Center - Augusta 4 .4
  WellStar Cobb Hospital 35 3.6
  Windy Hill Hospital 4 .4
  Winship Cancer Institute of Emory 
University 
119 12.4
  Total 961 100.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 104
Appendix C 
 
Georgia Counties  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
